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The purpose of this study is to improve the solubility, dissolution rate and permeability 
of poorly water-soluble drugs by understanding the mechanism of dissolution at 
molecular level of Flufenamic acid and Carbamazepine co-crystals in the presence of 
polymers. This study has been separated into four sections: (1) Formation of 
pharmaceutical co-crystals: Three pharmaceutical co-crystals of poorly water soluble 
active pharmaceutical ingredient (API) of Flufenamic acid (FFA) and Carbamazepine 
(CBZ) were synthesized, including 1:1 Flufenamic acid-theophylline co-crystal (FFA-
TP CO), 1:1 Flufenamic acid-nicotinamide co-crystal (FFA-NIC CO) and 1:1 
Carbamazepine-nicotinamide co-crystal (CBZ-NIC CO). The results of Fourier 
Transform Infrared spectroscopy (FTIR), Differential scanning calorimetry (DSC) and 
X-ray Powder Diffraction (XRPD) confirmed the formation of co-crystals. (2)  The effect 
of polymers on the surface dissolution of co-crystals: The influence of three polymers 
(polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), and a copolymer of N-vinly-2-
pyrrolidone (60%) and vinyl acetate (40%) (PVP-VA)) on the surfaces of FFA-TP CO, 
FFA-NIC CO and CBZ-NIC CO was studied using Atomic force Microscopy (AFM), 
Scanning electron microscopy (SEM) and Raman spectroscopy. It was found that the 
co-crystals have different dissolution mechanisms, and that addition of polymers can 
alter the dissolution properties of co-crystals by interacting with the crystal faces. (3) 
The molecular interactions between the drugs, co-formers and polymers were 
investigated using Nuclear Magnetic Resonance (NMR) and Diffusion Ordered 
Spectroscopy (DOSY). It was found that the type of a polymer, its concentration, and 
the interaction of the polymer with a co-former in solution will significantly affect the 
FFA and CBZ co-crystals (4). Molecular modelling of free drug molecules with co-
formers and polymers in the presence of water molecules: Results indicate bulk 
precipitation could be occurring for FFA molecules in solution and that PVP-VA was 
an effective precipitation inhibitor for all three co-crystals studied in solution.  Overall, 
PVP was an effective polymer for surface precipitation inhibitor and PVP-VA was the 
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Chapter 1: Introduction 
 
1.1 Research Background  
 
One of the major and common problems encountered by pharmaceutical industries 
are poor biopharmaceutical properties of drugs including low solubility, dissolution 
rate and intestinal permeability of drugs [1]–[4].  Majority of the new chemical 
entities developed in the pharmaceutical industries, 40% of existing drug products 
and up to 90% of new chemical entities, are insoluble in water. Poorly water soluble 
drugs lead to slow drug absorption and therefore inadequate and variable 
bioavailability [5]–[7]. Poorly water soluble drugs therefore require higher doses to 
produce a therapeutic effect [8].  
A key challenge to successfully developing new medicines is to enhance the 
solubility and dissolution rates of poorly soluble drugs in order to increase the 
bioavailability [9],[7]. This therefore provides a driving force to developing new 
approaches to designing new chemical entities with increased bioavailability such 
as salt formation, solid dispersion, particle size reduction, high pressure 
homogenisation and complexation [10]–[12]. Pharmaceutical co-crystals have been 
recognised as an alternative approach to provide new stable forms of drugs [3], 
[13]. As well as increased solubility and bioavailability, pharmaceutical co-crystals 
also provide various advantages such as improved stability, flowability and 
compressibility due to the different crystal structure of the co-crystals [8]. An 
exponential increase has been seen in the past decade on research in co-crystal 
structure and applications which is evident in the number of co-crystal structures 
deposited in the Cambridge Structural Database and co-crystal related patent 
applications [14]. 
A key limitation to this alternative approach however, is that a stable form of the 
drug is recrystallized during the dissolution of the co-crystals [7]. This leads to the 
loss of newly improved drug properties. To inhibit the recrystallization of the drug 
in aqueous solution, the effects of various polymers of different concentrations on 
the phase transformations and release profiles of co-crystals has been studied and 
has proven to be effective [4], [10], [11], [15]–[19]. Currently, only a small amount 
of study has been contributed into researching co-crystals and even less research 
into studying the interaction of polymers with co-crystals at molecular level using a 





This study probes into details of the molecular interactions of polymers of 
Polyethylene glycol (PEG), Polyvinyl pyrrolidone (PVP) and polyvinyl pyrrolidone-
vinyl acetate (PVP-VA), on the co-crystals of Flufenamic acid-Theophylline (FFA-
TP), Flufenamic acid-Nicotinamide (FFA-NIC) of Carbamazepine-Nicotinamide 
(CBZ-NIC) during surface dissolution and in solution. Atomic force microscope and 
scanning electron microscope were used to compare the etching patterns of 
different polymers followed by molecular dynamic methods used to calculate van 
der Waals and electrostatic interactions. Nuclear Magnetic Resonance (NMR) and 
Diffusion Ordered Spectroscopy (DOSY) was used to calculate the diffusion 





























1.2 Research aims and objectives 
 
The aim of this study is to investigate the effect of various polymers on the 
dissolution and phase transformation of single co-crystals of Flufenamic acid and 
Carbamazepine. Interactions of polymers on the surfaces of crystals will be studied 
at molecular level by a combination method of non-contact AFM, SEM, Raman and 
molecular modelling techniques. Interactions of drug molecule, co-former and 
polymer in solution will be studied by using both Nuclear Magnetic Resonance (i.e., 
1H NMR and DOSY) and molecular modelling methods.  
Objective 1: Review of pharmaceutical co-crystals definition, synthesis methods 
and characterization techniques. Review of molecular modelling and exploring the 
advantages and disadvantages of this technique. 
 
Objective 2: Synthesis of crystals, co-crystals, and single co-crystals of Flufenamic 
acid I (FFA), 1:1 Flufenamic acid-nicotinamide co-crystal (FFA-NIC CO), 1:1 
Flufenamic acid-theophylline co-crystal (FFA-TP CO), Carbamazepine III (CBZ), 
1:1 Carbamazepine-Nicotinamide (CBZ-NIC). Characterize these samples by using 
FTIR, DSC and XRPD.  
 
Objective 3: Use of non-contact Atomic force microscopy (AFM), Raman 
spectroscopy and Scanning electron microscope (SEM) to investigate the influence 
of polymers on the surface of single co-crystals in solution in the absence or 
presence of polymers.  
 
Objective 4: Understand the dissolution mechanisms and interactions of co-
crystals in solution in the absence and presence of pre-dissolved polymers at 
molecular level by using molecular modelling techniques.  
 
Objective 5: Apply one dimensional proton nuclear magnetic resonance (1H NMR) 
and Diffusion ordered spectroscopy (DOSY) to study the interaction between API, 
co-formers, and polymers in solution.  Molecular modelling techniques will also be 








1.3 Thesis structure 
 
This thesis will be presented in 9 chapters as follows: 
 
Chapter 1 will include a brief research background to the topic, research aims and 
objectives and the structure of the thesis.  
Chapter 2 will explore the biopharmaceutical classification system, methods for 
enhancing dissolution of poorly water-soluble drugs, crystallisation, single co-
crystals, Flufenamic acid co-crystals, Carbamazepine co-crystals, molecular 
modelling and molecular dynamics and the chapter conclusion.  
Chapter 3 will present the materials and methods used, preparation and synthesis 
for both experimental and computational methods and chapter conclusion.  
Chapter 4 will contain samples characterisation of all pure drugs, co-crystals and 
single co-crystals by use of ATR-FTIR, DSC and XRD followed by the chapter 
conclusion.  
Chapter 5 will explore the surface dissolution of single co-crystals in the 
presence/absence of polymers in solution by the use of non-contact AFM, Raman 
spectroscopy and SEM to detect any surface change. The polymers that will be used 
in this study are PEG, PVP and PVP-VA. Recrystallisation on the surfaces will be 
discussed here followed by the chapter conclusion.  
Chapter 6 will look at interaction of polymers on surfaces of single co-crystals by 
using computational methods. Cambridge structural database (CSD) will be used 
to predict morphology of the single co-crystals in order to gather information on the 
face index. Forcite module in Materials studio will be used to build the surface and 
the polymer system followed by running molecular dynamics in order to investigate 
the interactions between the different polymer and crystal surfaces.  The interaction 
energies and mean square displacement will be calculated and discussed followed 
by the chapter conclusion.  
Chapter 7 will explore the interactions of drug-drug, drug-polymer and co-former-
polymer in solution by investigating the chemical shifts of the characteristic peaks 
in the presence of polymers using NMR spectroscopy. Diffusion coefficient of the 





Chapter 8 will explore the interactions of free drug molecules, co-former molecules, 
and monomers in the presence of water molecules using molecular modelling 
techniques. Amorphous cell module in materials studio will be used to construct the 
system and Forcite will be used to run molecular dynamics. The interaction 
energies, length evolution and distribution, mean square displacement and radial 
distribution function will be calculated and discussed followed by the chapter 
conclusion.  
Chapter 9 will present the conclusions of this study followed by future studies.   
Appendix will present the additional and supplementary information related to each 




















Chapter 2 – Literature review 
 
2.1 Chapter review 
 
In this chapter, an introduction of the current approaches for improving the 
bioavailability of poorly water-soluble drugs are explored. This is followed by a 
comprehensive introduction and understanding of pharmaceutical co-crystals 
including co-crystals definition, co-crystals design mechanisms, co-crystals 
formulation methods and physicochemical properties and characterisation techniques. 
Following that, the problems encountered by co-crystals during the formulation phase 
are discussed such as solution mediated phase transformation and ways to overcome 
this challenge. The basic information about the materials used in this study is 
introduced, including FFA, NIC, TP, FFA-TP, FFA-NIC, CBZ, CBZ-NIC, PEG, PVP and 
PVP-VA. Finally, the molecular modelling and molecular dynamics are explored such 
as forcefields, geometry optimisation, dynamics and calculated properties. 
  
2.2 Biopharmaceutics classification system (BCS) 
 
Biopharmaceutical classification system (BCS) introduced into the Food and Drug 
Administration (FDA) has provided a mechanistic framework into differentiating 
drug absorption in terms of solubility and permeability [20]–[23]. All Active 
pharmaceutical ingredients (APIs) are classified using this framework during drug 
development, and helps in identifying the drugs that should not be clinically tested 
unless formulation strategies are put into place to enhance the solubility and 
permeability [24], [25]. This makes BCS a fundamental system in the development 
of oral drug products. If the highest strength of a drug is soluble in 250ml or less 
aqueous media over 1 – 7.5 pH, the drug is considered highly soluble [26]. 
Otherwise, the drug is considered poorly soluble.  
The different classifications of drugs in BCS, along with their solubility, permeability 











The high permeability and high solubility of Class 1 compounds allows high 
concentrations of the drug in the gut to saturate both efflux and uptake transporters. 
In-vitro-in-vivo correlation is expected if the dissolution rate is faster than the gastric 
emptying rate [26]. Dissolution and bioavailability of the drug are not rate limited. 
Class 2 drugs are likely to have the bioavailability to be dissolution rate limited. This 
therefore makes the class 2 drugs the focus for solubility enhancement studies due 
to their high permeability and consequently several approaches have been 
developed [20], [27]. For class 3 drugs, the bioavailability is permeability rate 
limited, therefore, in order to improve permeability, absorption enhancers are added 
in the formulation of the drug products [23], [26]. For class 4 drugs, bioavailability 
is limited by both dissolution and permeability. Enhancing solubility and dissolution 
alone might not help improve bioavailability. Poor solubility of these compounds 
can be overcome by new approaches to drug development which will be discussed 










2.3 Enhancing dissolution for poorly water-soluble drugs 
 
Factors such as first-pass metabolism, chemical stability, transport, solubility, and 
dissolution can limit the oral bioavailability of drugs in the body [28]. This can be 
overcome by chemically modifying the molecule to improve its bioavailability. 
However, this approach can result in significant alterations to the biological 
interactions of that molecule [29]. Therefore, modifying the bioavailability of a 
molecule is an attractive alternative but have only been slightly successful. 
Compounds with poor solubility are eliminated from the GI tract before they can 
fully dissolve and be absorbed into the blood stream [30], [31] . This results in low 
and irregular bioavailability and poor dose proportionality. Some of the methods for 
enhancing the solubility of poorly soluble molecules are mentioned below. 
 
2.3.1 Particle size reduction 
 
Particle size reduction is a promising approach to improve the invitro-dissolution of 
insoluble drugs [28], [32], [33]. When the surface area of particles is increased, this 
in turn increases a drug’s dissolution rate. Reducing the size of the particles 
therefore, is a method of increasing the bioavailability of drugs as the surface area 
is increased and the thickness of the diffusion layer is decreased [31]. Mechanical 
techniques to decrease the particle size of solids are classified in three categories: 
dry-milling, wet-milling, and high-pressure homogenization. Particles that need to 
be produced in the submicron (nano) range are produced by using techniques such 
as wet-media milling, piston-gap homogenization, and micro-fluidisation [34].  
Jinno et al. studied the effect of particle size reduction on dissolution and oral 
absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. Using 
hammer-milled, jet-milled and nanocrystal spray drying techniques, three different 
suspensions of different particle sizes were prepared. Their research showed an 
increase in dissolution rate and bioavailability with a reduction of particle size [32]. 
The most current research on particle size reduction has focused on a combination 
of two techniques, bottom-up and top-down [35]–[37]. The first process, bottom-up, 
produces drug nanocrystals by precipitating dissolved molecules. The second 
process, top-down, involves particle size reduction [38]. This combinative method 






2.3.2 Supercritical Fluid (SCF) Process 
 
SFC is a novel nanosizing and solubilisation technology for the reduction of particle 
size. Supercritical fluids are fluids whose temperature and pressure are greater 
than its critical temperature and critical pressure [39]–[42]. This asset allows the 
fluid to have the properties of both a liquid and a gas. At near-critical temperatures, 
SCFs are highly compressible and so can be used to pressurise a reactor 
containing drugs and polymeric excipients [41]. Once the drug particles are 
solubilised within the SCF, they are then recrystallised as smaller particles which 
improves the solubility and bioavailability. Carbon dioxide is the most widely used 
medium due to its low values of critical temperature (31.0°C), pressure (72.8 atm) 
and environmental pollution [40]–[42].  
SCF processes have been successfully applied for dissolution enhancement of 
Carbamazepine and Indomethacin. Moneghini applied SCF for the processing of 
Carbamazepine–PEG 4000 solid dispersions and Gong applied SCF for the 
formation and characterization of porous Indomethacin-PVP Co-precipitates [43], 
[44]. Kazarian researched the applications of supercritical fluids for polymer 
processing and found supercritical carbon dioxide to swell and plasticize polymers, 
which is crucial to the impregnation, extraction, and modification of polymeric 
materials. This in turn reduced the viscosity and facilitated the processing of 
polymers due to lower shear stresses [42]. 
 
2.3.3 Cyclodextrin complexation 
 
Cyclodextrins (CDs), are a group of oligosaccharides which are formed by glucose 
units binding together in a ring. Cyclodextrins can potentially increase the oral 
absorption of poorly water-soluble API by forming inclusion complexes [28], [45]–
[47]. 
Cyclodextrins can form complexes with drug molecules and improve their 
physicochemical properties without changing their structure. Cyclodextrins have a 
hydrophobic cavity interior with a hydrophilic exterior surface and they act as true 
carriers by dissolving and delivering hydrophobic drug molecules through the 
aqueous exterior of lipophilic biological membrane barriers [45].  Examples of such 





Various research has taken place in order to understand the complexes, 
mechanisms and its properties to improve the solubility of insoluble drugs.  
Wang applied cyclodextrin complexations to enhance stability and non-invasive 
pulmonary delivery of Resveratrol, a drug used for lung cancer treatment. Stability 
studies at pH 7.4 and in plasma indicated significant improvement in RES stability 
after complexation, with a much longer half-life [49].  
 
2.3.4 Solid dispersion 
 
Among the methods to improve bioavailability, solid dispersion (SD) is one of the 
most potent and successful methods. A solid dispersion is a drug–polymer two-
component system consisting of a hydrophilic matrix containing a hydrophobic 
drug. In solution, polymeric micelles are nanoscopic (>100 nm) structures that form, 
above a certain concentration named the critical micelle concentration (CMC) [50]–
[52]. They are formed when amphiphilic block copolymers composed of hydrophilic 
and hydrophobic chains self-assemble in water [51]. This results in enhanced 
surface area, leading to higher drug solubility and dissolution rate and therefore 
enhanced drug bioavailability. Enormous studies have shown that solid dispersion 
can enhance the drug release rate [2], [5], [53], [54].  
Onoue et al. designed efficacious formulations of curcumin, including nanocrystal 
solid dispersion (CSD-Cur), amorphous solid dispersion (ASD-Cur), and 
nanoemulsion (NE-Cur), to improve the physicochemical and pharmacokinetic 
properties. Their research showed significant improvement in pharmacokinetic 
behaviour in the newly developed formulations. ASD-Cur, CSD-Cur and NE-Cur 
showed a 12 fold, 16 fold and 9 fold increase of oral bioavailability respectively [55]. 
Yan et al. prepared novel valsartan-loaded solid dispersions with water, 
hydroxypropyl methylcellulose (HPMC) and sodium lauryl sulphate (SLS). The 
drug-loaded solid dispersion composed of valsartan/HPMC/SLS improved the drug 








2.3.5 High pressure homogenisation 
 
High pressure homogenization (HPH), is a technique widely used for the preparation 
of nano-suspensions of drugs that are poorly soluble in water [34], [36], [38]. HPH has 
been known to improve the solubility of poorly soluble drugs such as budesonide and 
omeprazole by effectively reducing the size to the nano-size range [31]. The poorly 
soluble drug is first dispersed in a suitable fluid, followed by being forced under 
pressure through a nano-sized hole (0.1-2mm) of a high-pressure homogeniser [57]. 
The suspension is passed through with a high velocity which follows a sudden pressure 
drop and turbulent flow conditions which reduces the size of the particles into 
fragments via collision [38]. The size of particles can be reduced from approximately 
30µm to 5µm [58]. Depending on the instrument available, the operating pressure for 
HPH ranges from 10 to 500 MPa [59].  
 
2.3.6 Pharmaceutical co-crystals 
 
Co-crystals are supramolecular systems in which one component is a poorly 
soluble active pharmaceutical ingredient (API) and the second component (co-
former) is a readily soluble compound fully digested in the body and involved in 
enzymatic reactions. Co-formers are readily soluble substances which are 
recommended for use in the food and pharmaceutical industries [60].  
 
Pharmaceutical Co-crystals have attracted a lot of interest in recent years as a 
potential method to improve the bioavailability of low soluble drugs by forming 
intermolecular interaction between the API and highly soluble co-formers by the 
formation of hydrogen bonding, π···π stacking interactions and van der Waals 
forces [3], [13], [61].  Co-crystals address the problems of poorly water soluble 
drugs by improving the dissolution and bioavailability rates [3], [13] . They are of 
an interest to the pharmaceutical industries due to their offering of a diverse range 
of solid-state forms for APIs that lack ionisable functional groups [61]. The crystals 
contain two or more molecules arranged in order, to create a new crystal that is 
superior to the parent molecule. The co-crystals differ from traditional solid-state 
API as the co-crystals are formed between a drug molecule and co-crystal former 
known as a co-former and are arranged in a crystal lattice. The components in a 
co-crystal are in a neutral state and interact via non-ionic interactions. A single co-





unbroken to the edges of the sample and contains no grain boundaries. Formation of 
API as co-crystals greatly improves the bioavailability, stability and manufacturing 
properties when compared to the parent crystalline drug of the same form [8].  
A wide range of co-formers are available to form co-crystals using APIs with low 
solubility in order to improve or maintain the solubility as compared to the parent 
drug [8]. Co-crystals with low solubility are not desirable for BSC II drugs as they 
require an improvement in the solubility and bioavailability. Co-crystals with a high 
solubility are also not desirable as they undergo a phenomena called solution 
mediated phase transformation [3]. Desirable cocrystals should have adequate 
solubility with a high bioavailability.  
Currently research in co-crystallisation is focussed on co-former selection. Very 
limited work has been carried out to identify a co-former that can form co-crystal 
with the desired in vivo and in vitro properties. The co-former selection rule that has 
been followed is that the solubility of the co-former should be approximately 10 
times higher than the API. 
 
2.4 Pharmaceutical co-crystals  
 
2.4.1 Co-crystal design mechanism 
 
Co-crystal screening is a crucial part of the overall process of investigating 
multicomponent structures. The compound of interest needs to be screened against 
a variety of co-crystal formers in order to discover new co-crystals which will then 
be characterised [14], [62]. The design of co-crystals involve  the  construction  of  
solid crystals with acceptable physical properties with respect to supramolecular 
structure assemblies [63]. 
The synthesis of new co-crystals is mostly affected by the nature of solvent and the 
reactants. For example, the presence of functional groups, the solubility of 
reactants in the solvent and the experimental conditions such as the stoichiometric 
ratio of the co-former and API, temperature, stirring and pH [14], [64], [65]. The 
bioavailability and chemical stability of co-crystals are dependent on the non-
covalent interactions in the crystal structures such as hydrogen bonding, van der 





To design co-crystal systems, the rules of hydrogen bonding, supramolecular 
synthons, and graph sets could be used. Successful formation of hydrogen bonds 
between two molecules involves designing appropriate donor and acceptor 
moieties that will engage in the interaction. A common approach is to use 
supramolecular synthons, which exist as homosynthons or heterosynthons [68], 
[69]. Synthons are defined as ‘structural units within a molecule that can be 
assembled using known synthetic operations’ [70]. Using this strategy, hydrogen 
bonding between functional groups can be predicted and co-crystal structures can 
be proposed. Homosynthons contain identical functional groups that exhibit 
molecular complementarity, and they are often deemed ‘self-association motifs’ 
and heterosynthons contain non-identical functional groups, but they also exhibit 
molecular complementarity [71]. The figure below shows examples of synthons 
based on hydrogen bonds: homosynthons and heterosynthons. 
 
Figure 2 - examples of homosynthons and heterosynthons 
 
There are several stages for designing, formation and testing an ideal 
pharmaceutical co-crystal. This can be broken down into steps as shown in the 
diagram below.  
Figure 3 - Stages of designing a co-crystal 
 
A widely used strategy in crystal engineering is to first investigate the crystal 





aid in the formation of new supramolecular synthons between the target API and 
co-former [72]. 
Because co-crystallisation experiments can be time consuming, computational 
techniques based on molecular modelling [73]–[75]  molecular descriptors [76], 
[14], and hydrogen bond propensity [77] have been developed to steer the search 
for new co-crystals. These approaches have succeeded in broadening the 
understanding of the principles behind co-crystallisation.  
 
2.4.1.1 Co-former selection 
 
Co-former selection is a crucial step in the design of pharmaceutical co-crystals as 
the different physicochemical properties of selected co-formers play a part in the 
in-vivo properties of the produced co-crystals. The Cambridge Structure Database 
(CSD) and “supramolecular synthon approach” was applied to effectively screen 
suitable co-formers for co-crystal development [78]. Although the design strategy was 
accelerated by using both these approaches, prediction of the physicochemical 
properties of the resulting co-crystals remained challenging [79].  
Much research has gone into selection of suitable co-formers for improved co-crystals 
[80]–[82]. Tomaszewska studied the importance of in-vivo conditions and the type of 
co-former for Carbamazepine saccharin (CBZ-SAC) and Carbamazepine- 
nicotinamide (CBZ-NIC) and concluded that the characteristics of the co-former define 
a critical variable for dissolution of pharmaceutical co-crystals with important 
implications for their in vivo performance [83].  
 
2.4.2 Co-crystal formation methods  
 
A wide range of successful co-crystal preparation methods have been documented 
over the years such as solvent evaporation [54], [84], solid state grinding [85], 
solution crystallization [86],[87], slurry conversion [14], melt crystallization [88], hot 
melt extrusion [16], and spray crystallization [89]; with slow evaporation from 





For the solvent-based methods, the selection of the solvent is crucial since a 
suitable solvent alter the intermolecular interactions and potentially lead to better 
crystallisation results. Other methods may also have limitations [90], such as: 
• Thermal methods that require melting needs high temperatures and can affect the 
stability of heat-sensitive compounds. 
•Mechanical methods, such as grinding can produce amorphous materials, limiting 
their effectiveness if a suitable solvent is not used. 
• Methods based on precipitation from solution require continuous and precise 
control of the supersaturation level of the components’ concentration . The use of a 
solvent is also not environmentally friendly. 
 




2.4.2.1 Solution based methods  
 
The most conventional method used for crystal formation is the use of suitable 
solution with proper degree of supersaturation. The supersaturation of a solution is 
the driving force for crystallization. There are two concentrations to consider within 
the co-crystal system: the API concentration and the conformer concentration. 
These concentrations in relation to the co-crystal solubility is what dictates the 





















Eutectic points offer an experimentally accessible method to assess co-crystal 
solubility and stability regardless of the solubility relationship between co-crystal 
and drug. A co-crystal eutectic point is a point where two solids, API and conformer, 
and a solution coexist in equilibrium [81].  
 
Eutectic points will exist for the system where at one fixed solution concentration: 
(i) The co-crystal and the target molecule are stable.  
(ii) Mixture of the co-crystal and conformer are present. 
 
The eutectic point represents the solution minima; if the solvent content is low, 
solubility will be high. The co-crystal will only be stable at concentrations that lie 
between the eutectic points. Knowledge of this concentration range is key to 
designing a successful solution co-crystallisation process. Operation outside of this 
range can fail to yield a co-crystal or can yield a mixture in the solid phase such as 
co-crystal and co-former [92].  
 
The behaviour of a mixture of two crystalline compounds and a solvent can be 
visualized and explained by using ternary phase diagram [87]. The ternary phase 
diagram (TPD) shown below represents the solubility of a co-crystal system in each 
given solvent at a fixed temperature and pressure.  
 
 
Figure 5 - Schematic representation of isothermal ternary phase diagram 
 
 




When A and B form a compound AB of stoichiometry 1:1, the ideal solubility of AB is 





solid A is in equilibrium with solution; (B) Acocrystal + ABcocrystal + solution, solid A and AB 
(cocrystal) are in equilibrium with solution; (C) ABcocrystal + solution, solid AB is in 
equilibrium with solution; (D) Bcocrystal + ABcocrystal + solution, solid B and AB are in 
equilibrium with solution; (E) Bcocrystal + solution, solid B is in equilibrium with solution; 
(F) Solution (A+B+AB), A or B and AB are completely dissolved in the solvent [93]. 
 
In Figure 6 (a) the solubility of A and B are similar in solvent and therefore solution 
crystallization with equimolar reactants will result in a 1:1 AB co-crystal by solvent 
evaporation. Components with non-equivalent solubility in solvent in shown in 
figure 6(b) where the resulting co-crystal formed by solvent evaporation may lead 
to producing the pure starting crystalline materials, or mixture of co-crystals and 






The most common method of solution crystallisation is evaporative crystallisation. 
This method involves the nucleation and growth of a co-crystal from a solution 
consisting of both co-formers and API in a solvent [64]. The supersaturation of the 
solution is provided by the removal of the solvent from the solution via evaporation. 
A slow rate of evaporation is usually desired to form a smaller number of larger 
crystals as opposed to a high number of smaller crystals. Once the crystals are 
formed, they are harvested and dried [95].  
The biggest challenge to evaporative crystallisation is the reproducibility and 
homogeneity which can prove difficulties due to a lack of control over crystallisation 




Cooling crystallisation has drawn a lot of attention due to its potential for large scale 
co-crystal production [79]. In cooling crystallisation, the temperature of the 
crystallisation system is varied by firstly heating the mixture containing drug, co-
former and solvent to high temperatures, followed by the cooling down step. Co-
crystals will precipitate when solution becomes supersaturated as the temperature 
drops down. Cooling crystallisation is the preferred choice currently for industrial 
crystallisation of pharmaceuticals as it can provide more control over the production 






Fucke screened piroxicam against 20 different co-formers and found that the 
cooling experiments - fast and slow – resulted in 39 crystalline products of which 
21 could be identified as co-crystals [96]. 
The co-crystal formation rate of Theophylline-benzoic acid by monitoring it using 
on-line Raman spectroscopy was investigated by Yaohui Huang. The nucleation 
time, nucleation temperature and cooling ending point can be gained from results 
of on-line Raman monitoring [97]. 
 
 
2.4.2.2 Solid state formation methods  
 
Solid state formation of pharmaceutical co-crystals has attracted great interest due 
to the advantages provided by these processes. They are synthesised in the 
absence of solvents or by using very small amounts, have excellent purity and 
quality and provide a high throughput with fast processing times [64].  
 
The grinding methods 
 
Solid state grinding is an alternative synthetic method to solution-based co-
crystallization process. The reduction of particle size is carried out in the mixture 
which in turn increases the covalent reactivity [63], [64], [98].  
Solvent drop grinding involves grinding two materials together i.e., solid-state 
grinding with incorporation of small quantity of solvent. The solvent used will act as 
catalyst. Fucke compared three different methods: crystallisation from the melt, 
from solution and solvent-drop grinding for the co-crystal formation of piroxicam 
with 20 different co-crystals and found that solvent-drop grinding showed the 
highest absolute number of experiments resulting in co-crystals [96]. 
 
Hot melt extrusion 
 
Hot melt extrusion is a manufacturing process which has significant potential in 
continuous pharmaceutical manufacturing process [99]. Hot melt extrusion involves 
the formation of co-crystals by use of highly efficient mixing and improved surface 





optimize and make the process more flexible as well as aid in carrying out the 
process in lower temperatures.    
Liu investigated the chemical stability of CBZ-NIC co-crystals and found that 
preparation of CBZ-NIC CO by hotmelt extrusion significantly depresses the 
processing temperature (190°C to 160°C) and thus minimises the thermal 
degradation of the heat-sensitive drug [100]. 
 
2.4.2.3 Other methods 
 
Alhalaweh and Velega studied the formation of Co-crystals from stoichiometric 
solutions of incongruently saturating systems of 6 different co-crystals by spray 
drying and found that pure co-crystals were formed in comparison to solvent 
evaporation [101]. Ober and Gupta formed co-crystals of Itraconazole-succinic acid 
by gas antisolvent crystallisation method and found that the co-crystals remained 
stable for up to 4 weeks against thermal stress [102]. 
Chow formed co-crystals of Ibuprofen and Flurbiprofen with Nicotinamide through 
rapid solvent removal using rotary evaporation and found that co-crystallisation with 
nicotinamide can simultaneously improve tableting behavior, hygroscopicity, and 
dissolution performance of ibuprofen and flurbiprofen [62]. 
Müllers investigated the formation and micro-ionisation of ibuprofen-nicotinamide 
co-crystals by rapid expansion of supercritical solutions (RESS) using CO2 and 
found that the surface area of the co-crystals increased by a tenfold in comparison 
to co-crystals formed by the slow evaporation method. This in turn decreased the 
mean evaporation time. RESS offers an advantage of combining micro-ionisation 
and co-crystallisation for drugs with dissolution limited bioavailability [84]. 
Daurio investigated the application of twin-screw extrusion (TSE) as a scalable and 
green process for the manufacture of co-crystals of Caffeine-Oxalic acid, 
Nicotinamide-trans cinnamic acid, Carbamazepine-Saccharin, and Theophylline-
Citric acid. TSE resulted in being an effective method to make co-crystals for all 
four systems studied [103].  
Many techniques as mentioned above are capable of producing co-crystals. 
However, a challenge remains in the control of the nucleation, crystallisation and 
the phase evolution of the co-crystals [104], [105]. Although many technological 





is still not fully understood [102]. Therefore, many efforts have been put into 
understanding the underlying mechanism of these techniques. Techniques that 
probe a reacting system in situ are preferred and remain experimentally 
challenging.  
Mandala reported a solid-state in situ NMR study of the spontaneous formation of 
a co-crystal between the API caffeine and co-former malonic acid. The study found 
that during the reaction, the technique provided subtle clues to the mode of mass 




Salt formation is currently one of the primary solid-state approaches used to modify 
the physical properties of APIs. However, a major limitation is that the API must 
possess a suitable site for ionisation. In comparison, co-crystals consist of an API 
which regardless of acidic, basic, or ionizable groups, could potentially be co-
crystallised [65]. 
It is crucial to investigate the physical and chemical properties of a co-crystal to 
determine whether it can be developed into a marketed dosage form. Properties 
such as crystallinity, melting point, solubility, stability and dissolution of a co-crystal 
needs to be studied at the early stages of development [65]. Changing the 
properties can improve the stability and efficacy of a dosage form while maintaining 
its pharmacological activities [107]. Currently, there are over 100 studies of co-
crystals that have exhibited improved solubility and/or dissolution rates with 
improved physical and chemical stability [108]–[110]. 
The main properties of pharmaceutical co-crystals are as follows: 
 
2.4.3.1 Melting point  
 
The melting point of a compound is generally used as a method of characterization or 
purity identification and are used to evaluate the energy of a crystal lattice [111]. It is 
hypothesized that by co-crystallizing an API of interest with a co-former with a similar 
melting point, can fine tune the melting point and aqueous solubility of the API [79]. 





crystal changes with respect to the individual components and whether the melting 
points can be estimated and regulated within a co-crystal system [62] [112].  
Liu used melting method and hot melt extrusion to depress the processing temperature 
of Carbamazepine-nicotinamide (CBZ-NIC) co-crystals in solid dispersions and thus 
minimizing the thermal degradation of the heat sensitive Carbamazepine. It was found 
that chemically stable amorphous solid dispersions were prepared which had a 
significant increase in the dissolution rate [100]. Nechipadappu studied the thermal 
analysis of Flufenamic acid with 2-chloro-4-nitrobenzoic acid (CNB) and ethenzamide 
(ETZ) using DSC and found that melting peak temperature for the co-crystals FFA-
CNB and FFA-ETZ was found at 143.93°C and 97.28°C, respectively. It was observed 
that FFA-CNB co-crystal melts exactly in-between the melting point of its constituent 
starting materials, whereas FFA-ETZ co-crystal melts at low temperature compared to 
its starting materials. This was due to the loose crystal packing of FFA-ETZ co-crystal 





Stability is a heavily studied parameter during the development of new chemical 
entities. Depending on the structure and the characteristics of a molecule, different 
types of stability tests need to be carried out. Chemical and physical stability are 
usually studied at accelerated stability conditions to determine developability and shelf 
life [65]. It is also critical to determine the stability of co-crystals in solution as 
precipitation could occur of the parent drug in a process known as solution mediated 
phase transformation. 
Common stability tests include relative humidity tests [114], thermal stress tests [115], 
chemical stability [116] and thermal stability [117].  
 
Trask subjected theophylline co-crystals to relative humidity challenges in order to 
assess their stability in comparison to crystalline theophylline anhydrate, and caffeine 
co-crystals. The study showed none of the co-crystals converted into a hydrated co-
crystal upon storage at high relative humidity [118]. 
Tsutsumi studied Miconazole salts and co-crystals to improve the physicochemical 
properties of miconazole. Stability tests of preliminary formulations prepared with each 
crystal form indicated that maleate (salt) and hemifumarate (co-crystal) were unstable 
at 80 °C and generated a specific degraded product, i.e., a Michael addition, between 





2.4.3.3 Mechanical properties 
 
Study of the mechanical properties of drugs are important for bulk powder compaction 
and tableting. Compaction includes compression (volume reduction and particle 
rearrangement) and consolidation (interparticle bond formation) [119]. 
The mechanical deformation mechanisms of solid materials are elastic, plastic, 
viscoelastic, and fragmentation [120]. The elasticity of a material is the ability to 
undergo reversible deformation under an externally applied stress. Upon removal of 
the stress, the material should exhibit no residual deformation. Plastic deformation on 
the other hand, is permanent and irreversible [121]. In order to produce stable, intact 
tablets, it is crucial to study the mechanical properties of the co-crystals. The 
relationship between crystal structure and mechanical properties have been 
investigated thoroughly. 
 
Chattoraj studied the Origin of Deteriorated Crystal Plasticity and Compaction 
Properties of a 1:1 co-crystal between Piroxicam and Saccharin and found that the 1:1 
co-crystal between piroxicam and saccharin exhibits significantly deteriorated powder 
compaction properties compared to both the co-formers [122]. 
Ahmed studied the relationship between mechanical properties and crystal structure 
in co-crystals and salt of paracetamol and reported that it was possible to explain the 
improved mechanical properties of powders based on the crystal structure [123]. 
Hiendrawan studied the physicochemical and mechanical properties of paracetamol 
co-crystal with 5-nitroisophthalic acid and reported that the co-crystal displayed 
superior tabletting performance in comparison to the API alone [124]. 
 
2.4.3.4 Solubility  
 
Co-crystallisation can dramatically change the properties of API, particularly the 
increased solubility and dissolution rate of the API [8], [120], [125]. The overall effect 
of a co-former on the co-crystal solubility is dependent on the solvation energy of the 
components and the co-crystal lattice energy. A highly soluble co-former can form 
strong solvent-solution interactions and can promote co-crystal dissolution, which then 







When studying the solubility of co-crystals, it is important to consider the equilibrium 
vs kinetic solubility measurements and the form changes of the API [62], [78]. 
Equilibrium vs kinetic solubility measurements are usually based on one measurement 
at one time point. Equilibrium solubility is dependent on the concentrations of the drug 
and co-former in solution and provides insight about the origin of the co-crystal solution 
phase behaviour. This information is crucial for addressing the limitations of poorly 
soluble drugs [127]. Kinetic solubility shows the dissolution rate of the co-crystals and 
indicates apparent solubility due to the instability of the co-crystal in solution  [128]. 
Form change of an API can be revealed by taking various time point measurements to 
detect a decrease in concentration. This indicates the crystallisation of the less soluble 
form of the API, a process known as solution mediated phase transformation [65].  
 
Ren studied the effects of pH, surfactant, ion concentration, co-former, and molecular 
arrangement on the solubility behavior of myricetin co-crystals and observed that 
kinetic solubility of myricetin co-crystals was modulated by pH and co-crystal co-former 
(CCF) ionization in buffer solution. The results also indicated that the solubility of MYR 
co-crystals was increased in a concentration dependent fashion by the surfactant or 
ion concentration [129]. 
 
Bethune studied the effect of co-crystal components on the pH and co-crystal solubility 
and found that Carbamazepine-salicylic acid and Carbamazepine-4-aminobenzoic 
acid revealed co-crystals of a nonionizable drug when co-crystallized with ionizable 




Using co-crystallisation to improve bioavailability of poorly water-soluble drugs have 
attracted a lot of interest over the years [91], [131] . Despite the current interest, a very 
limited number of animal bioavailability studies for co-crystal forms of APIs have been 
reported to date. 
Jung studied the bioavailability of Indomethacin-saccharin co-crystals in beagle dogs. 
Results showed that the in‐vitro dissolution rate of the co-crystals was higher than that 
of IND and the in‐vivo bioavailability of the IND–SAC co-crystals in dogs was 
significantly higher than that of IND [132].  
Smith  synthesised and studied the dissolution and bioavailability of Co-crystals of 





vastly superior to those of quercetin alone. Furthermore, the co-crystals showed an 
increase in bioavailability of up to 10 fold [131].  
 
2.4.4 Characterisation techniques 
 
Understanding the structural information and physicochemical properties of co-crystals 
is essential for co-crystal research and synthesis. Various techniques have been used 
to characterize co-crystals. 
Co-crystals can be characterised using powder X-ray diffraction (XRPD), single co-
crystal X-ray diffraction (SXRD), Raman spectroscopy, Infrared spectroscopy (IR) and 
differential scanning calorimetry (DSC) [79], [133], [134]. More information on the 
characterisation techniques are presented in Chapter 3.  
 
2.5 Pharmaceutical co-crystal Formulation and 
Development  
 
To successfully develop new drug candidates and acquire the desired therapeutic 
performance, it is essential to improve the solubility of poorly water-soluble drugs. 
Pharmaceutical co-crystals have been demonstrated to be an effective tool for 
enhancing the solubility by creating a supersaturated state of poorly water-soluble 
drugs [79], [128], [134], [135]. However, co-crystals in solution are not 
thermodynamically stable which leads to a phenomenon called solution-mediated 
phase transformation (SMPT) where the drug recrystallises from a metastable form to 
a stable form either in solution or on the surface of the dissolving solid [136]. This 
phenomenon can be overcome by using precipitation inhibitors [7] and the spring and 
parachute model [137].  
 
2.5.1 Solution mediated phase transformation 
 
Pharmaceutical development of drugs with thermodynamically metastable forms is 
usually desired due to their higher solubilities and faster dissolution rates. However, 
the metastable forms are undesirable in some cases because of recrystallization of the 





dissolution [138]. Recrystallisation of the drug usually occurs during the dissolution 
process which decreases the concentration of the drug, which then reduces the 
absorption rate and therapeutic effect [136].  
This phenomenon has been studied extensively by our research group for 
Carbamazepine and Flufenamic acid. Qiao monitored the in-situ Carbamazepine-
nicotinamide co-crystal intrinsic dissolution behaviour and reported that compared with 
CBZ III and I, the rate of intrinsic dissolution rate of CBZ–NIC co-crystal decreased 
slowly during dissolution. In situ solid-state characterisation was also performed which 
showed the change of CBZ–NIC co-crystal and polymorphs to its dihydrate form [139].  
Guo studied Flufenamic acid co-crystal dissolution in the presence of a polymer in 
solution and reported that that the dissolution mechanisms of FFA-TP CO are 
controlled by the defect sites of the crystal surface. Precipitation of the parent drug 
FFA occurred as individual crystals in the bulk fluid. On the other hand, the dissolution 
mechanisms of FFA-NIC CO are controlled by surface layer removal and by a surface 
precipitation mechanism. The parent drug FFA precipitates directly onto the surface of 
the dissolving co-crystals [140]. 
Although many researches has gone into understanding SMPT, understanding the 
kinetics behind the transformation remains challenging [141].  
Three essential processes are involved in SMPT: 
(i) Dissolution of the metastable solid 
(ii) Nucleation of a more stable solid phase 
(iii) Growth of the stable phase 
 
The nucleation and growth of the more stable phase often occur on the metastable 
phase, reducing the dissolution rate of that API [136]. The metastable solid first 
dissolves creating a supersaturated solution containing the thermodynamically stable 
solid. Supersaturation causes stable phase of the solid to nucleate and grow, often on 
the surface of the metastable solid [142]. This reduces the enhanced properties of the 
co-crystals and reduces the solubility and dissolution rates. The process of nucleation 
and grown depends on factors such as supersaturation, interfacial tension, and 
temperature of the solution [143]. Precipitation can occur either on the surface of 
crystals where the nucleation and growth occur on the surface molecules present in 
the crystal or in the bulk solution where nucleation and growth occurs between the 





 2.5.2 Precipitation inhibitors 
 
Extensive research on precipitation inhibitors have showed that solubility of poorly 
soluble drugs can be improved by the addition of polymers or surfactants [52], [54], 
[109], [145]. Polymers, including  polyvinylpyrrolidone (PVP K30), polyvinylpyrrolidone 
K90 (PVP K90), polyethylene glycol (PEG 6000) and hydroxy propyl methyl cellulose 
(HPMC), have been reported to enhance the solubility of co-crystals [140]. Surfactants 
promote drug solubility by the formation of micelles of the additive and API while 
polymers form specific molecular interactions with the API and solution. The key 
factors which play a part in the inhibition effect include the hydrophobic level of 
additives and the ability of the polymers to form hydrogen bonding with the API [146]. 
Polymers inhibit nucleation by forming intermolecular interaction with the API during 
the embryo formation of the solute molecules and disrupt the self-assembly. 
Induction/nucleation time is the time span between the supersaturated solution to the 
formation of the first nuclei and acts as a useful method for understanding the kinetics 
of the nuclei formation [147]. The amount of induction time required, or nucleation is 
dependent on the strength of the interactions between the API and additives which is 
determined by hydrogen bonding and van der Waals interactions [148].  
The additives inhibit crystal growth by attaching onto the growth site and act as a 
mechanical barrier. Additives can attach themselves in two ways: reversible physical 
absorption which includes van der Waals and electrostatic forces, and irreversible 
chemical absorption which include covalent bonding [149], [150]. The key factors that 
facilitate adsorption of polymers on crystal surfaces are hydrophobic interactions, 
electrostatic interactions, and hydrogen bonding [12], [151].  
 
2.5.3 Spring and Parachute model 
 
In order to improve the oral absorption of a poorly water-soluble drug, a method called 
‘spring and parachute’ (Figure 6) has been widely used to promote and maintain the 
supersaturation of the API [150], [152]. The high energy form of the drug which rapidly 
dissolves to generate a supersaturated solution then immediately precipitates, is 
referred to as the ‘spring’. The additives, which act as precipitation inhibitors, are 
referred to as the ‘parachute’ as they have to ability to maintain the supersaturation of 





increase the bioavailability [153], [137].  The figure below shows a diagram of the 
‘spring and parachute’ model. 
Figure 6 - Spring and parachute model 
 
 
Liu studied the oral bioavailability of Sorafenib by Optimizing the “Spring” and 
“Parachute” based on molecular interaction mechanisms. It was observed that the 
solubility of sorafenib could be increased ∼50-fold in the coexistence of 
poly(vinylpyrrolidone-vinyl acetate) (PVP-VA) and sodium lauryl sulphate (SLS). 
However, SLS impaired the ability of PVP-VA to act as an efficient “parachute” to keep 
the drug in solution and maintain drug supersaturation. It was concluded that despite 
its forceful “spring”, the formulation containing both PVP-VA and SLS showed a 
moderate bioavailability enhancement, due to the lack of an efficient “parachute” [154]. 
 
2.6 Flufenamic acid CO, Carbamazepine CO, and their 
coformers 
 
2.6.1 Flufenamic acid drug introduction 
 
Flufenmaic aicd is a nonsteroidal anti-inflammatory drug belonging to the group 
fenamates. It contains the functional group of N-phenylanthranilic acid which 
contributes to the anti-inflammatory properties [155]. FFA, together with mefenamic 
acid is considered as one of the most potent NSAIDs and is used for the treatment of 
lower back pain and can be administered orally or topically [156]. Flufenamic acids 





has low solubility and high permeability and belongs to class II of the 
biopharmaceutical classification system.  
FFA has a solubility of 0.00909g/l and permeability of logP = 5.25 [157]. Research 
carried out by Guo in 2014 reported that the melting points of FFA form III and FFA 
form I was 126.5°C and 134°C respectively [146]. Form I is stable above 42°C while 
form III is stable at room temperature. FFA has been reported to show a potency of 16 
times higher than that of aspirin and 3.2 times of Mefanamic acid [158].  
 





2.6.2 Flufenamic acid co-crystals synthesis 
 
Much research have been carried out on FFA co-crystals and single co-crystals using 
co-formers such as Nicotinamide, 2-pyridone, Theophylline and 4-4’-bipyridine. Fabian 
et al. reported a 1 : 1 co-crystal of FFA with a pharmaceutically acceptable co-former, 
nicotinamide [155]. Lee described the epitaxial sublimation behaviour of a structurally 
related compound, mefenamic acid on the (100) faces of Flufenamic acid form I and 
III single co-crystals [159]. However, there is still a lot to understand about co-crystals 
and single co-crystals such as dissolution behaviours at molecular level. In this 
research, FFA-NIC and FFA-TP co-crystals and single co-crystals were synthesised in 
order to look at dissolution of the surface molecules at molecular level.  
Delaney and Korter investigated FFA-NIC CO using terahertz spectroscopy and solid-





binding energy, driven by increased intermolecular hydrogen bond strength and 













2.6.3 Carbamazepine drug introduction 
 
Carbamazepine is an antiepileptic drug that has been in use for several decades to 
treat seizures and nerve pain. It was introduced for pharmaceutical use in the late 
1960s [161]. In recent times, it has been approved for its anticonvulsant role in 
administrations in patients with epileptic problems or as a pain reliever in trigeminal 
neuralgia, the mechanism of action being associated with the modification of synaptic 
transmission [162]. 
CBZ was also evaluated as a possible therapeutic scheme for bipolar disorder [163], 
attention-deficit hyperactivity disorder [164], schizophrenia [165], and other psychiatric 
disorders [166], [167]. CBZ has low water solubility therefore requires a higher dose in 




Figure 8 - (a) below shows the bonding between FFA-TP CO. Figure (b) shows the 










2.6.4 Carbamazepine co-crystals synthesis 
 
One strategy used for the formation of CBZ co-crystals involves the breaking of the 
amide-amide dimer and forming a supramolecular heterosynthon between CBZ and a 
co-crystal former [168]. Formation of CBZ into a co-crystal has shown significant 
improvement in the physicochemical properties. CBZ co-crystal solubility varies 
greatly, demonstrating 2 to 152 times greater than the stable CBZ dihydrate [169]. Qiao 
investigated the dissolution and phase transformation behaviour of Carbamazepine–
nicotinamide (CBZ–NIC) co-crystals using in situ techniques of UV imaging system 
and Raman spectroscopy, and demonstrated that the enhancement of the apparent 
solubility and dissolution rate has been reduced significantly due to its conversion to 
CBZ DH [139]. 
 
2.6.5 Pharmaceutical co-formers Nicotinamide and Theophylline 
 
Nicotinamide (NIC) was chosen as a co-former for FFA and CBZ due to its high 
solubility. NIC is a suitable co-former due to its high likelihood of hydrogen bond 
forming between the carboxylic acid present in FFA structure and nitrogen atom 
belonging to NIC.  
NIC is classified as a Class I drug and is often utilized in much larger doses than seen 
in co-crystal formation to treat high cholesterol [170]. It has four known polymorphs, I-
IV, Form I is the stable and the others are metastable [171].  The melting points of 
Forms I, II, III and IV were 126–128°C, 112–117°C, 107–111°C and 101–103°C, 





ibuprofen [173] and 3-hydroxybenzoic acid, 4-hydroxybenzoic acid, Carbamazepine 
and other APIs [174], [175].  
The solubility of NIC in water is about 570 mg/ml at 37˚C. In his research, Rahman 
looked at co-crystallisation of CBZ with NIC and concluded that the pre-formulation 
profile of the co-crystals was similar to CBZ, except that it had an advantageous 
resistance to hydrate transformation [176].  
 
Figure 10 - Structure of Nicotinamide 
 
 
Theophylline was chosen as a co-former for FFA. Theophylline is a drug used for 
respiratory diseases, which can act as hydrogen-bond donors and hydrogen-bond 
acceptors [177].  In a previous research, Aitipamula investigated the physicochemical 
properties of FFA-TP and compared it with a reported FFA co-crystal with 
nicotinamide. Properties such as stability, hygroscopicity, solubility, and dissolution 
rate were measured and was found that FFA·TP was offered better solubility and 
dissolution rate [157]. 
 















2.7 Introduction to polymers 
 
Polymers can enhance crystallisation of co-crystals by forming ternary complexes or 
co-complexes between the co-crystal and polymer [11]. Polymers such as water-
soluble cellulose derivatives can form complexes with FFA-TP that have different 
physicochemical properties than those of FFA alone [178]. When added in small 
amounts, water-soluble polymer agents enhance co-crystal solubilizing effect by 
increasing the apparent complex stability constant. The polymers, due to their direct 
participation in drug complexation, improve both pharmaceutical and biological 
properties of co-crystal complexes, independent of drug's physicochemical properties 
[141], [150].  
 
2.7.1 Polyethylene glycol 400 
 
PEG 4000 is a commonly used pharmaceutical polymer with a melting point of 50-
58°C [179]. It has a high molecular weight of about 3500-4500 and its solubility in water 
is 50 mg/ml at 25°C [180]. PEG has been extensively used as carriers for solid 
dispersion [181] due to its favourable properties such as low melting point, rapid 
solidification rate, capability of forming solid drug solutions, low toxicity and low costs 
[182]. PEG is a hydrophilic polymer that can enhance the dissolution, solubility and 
have the ability to prevent the re-crystallization of drug by forming hydrogen bonding 
with the drug [163]. PEG 4000 has been studied in our research group as a potential 
polymer to inhibit recrystallisation of API in co-crystals. Guo investigated the influence 
of polymers on supersaturated Flufenamic acid co-crystal solutions and reported that 
the supersaturated co-crystal solutions with pre-dissolved PEG demonstrated more 
effective stabilization in comparison to the pure FFA in the presence of the same 
polymer [146]. 
 






2.7.2 Polyvinyl Pyrrolidone K30 
 
Polyvinyl pyrrolidone (PVP) has good solubility in a wide variety of organic solvents 
therefore it is suitable for the preparation of solid dispersions by the solvent method 
[183], [184]. The average molecular weight of PVP K30 is 40000 with Tg at 165.03°C. 
PVP is widely used as an excipient in the pharmaceutical industry. It is not regarded 
as toxic when given orally due to its high molecular weight and inability to pass through 
the membrane of the GI tract [185].  PVP has also been found to stabilize the 
supersaturated condition of drugs by forming hydrogen bonding, such as with 
indoprofen [186] and BMS-488043 [187]. The functional groups =N- and C=O are likely 
to form hydrogen bonding with other molecules.  The carbonyl group is preferred for 
hydrogen bonding in comparison to the nitrogen atom because the steric hindrance 
present in the nitrogen atom interrupts the intermolecular interactions [188]. Kothari 
studied the role of drug–polymer hydrogen bonding interactions on the molecular 
mobility and physical stability of nifedipine solid dispersions and reported that PVP was 
the best polymer to use in terms of drug–polymer hydrogen bonding, the structural 









2.7.3 Plasdone S630 (PVP-VA) 
 
PVP-VA is an amorphous copolymer of N-vinyl-2-pyrrolidone (60%) and vinyl acetate 
(40%) with an average molecular weight of 51000. It is a white, odourless powder and 
is more hydrophobic than PVP. Due to the presence of vinyl acetate groups, PVP-VA 
has a lower Tg 106°C compared to PVP. This makes it very soluble in water and many 
organic solvents. PVP-VA contains two strong hydrogen bonding acceptors of C=O of 
vinylpyrrolidone and C=O vinyl acetate group.  





PVP-VA acts as a good binder for the direct-compression of tablets, drug granulation 
and for coating materials of control release drugs [190]–[192]. It is also a good 
stabilizer for preventing drug crystallization and many researches has reported the 
inhibition of crystal growth rate such as of bifonazole and nimesulide [193] in the 
presence of PVP-VA. Knopp investigated the influence PVP/VA) on the non-sink in 
vitro dissolution behaviour and in vivo performance of celecoxib (CCX) amorphous 
solid dispersions. Knopp reported that the hydrophilic monomer vinylpyrrolidone (VP) 
was responsible for the generation of CCX supersaturation whereas the hydrophobic 
monomer vinyl acetate (VA) was responsible for the stabilization of the supersaturated 
solution [194]. 
 




2.8 Molecular modelling and molecular dynamics 
 
Molecular modelling, a computer-based technique, can be used for deriving, 
representing, and manipulating the structures and reactions of molecules. Due to the 
advancement of computers, the development of molecular modelling has increased 
largely in the last couple of years. For several decades, theories have been linked with 
molecular modelling or quantum mechanics and this technique has been applied to 
understand the electronic properties and chemical reactivity [195]. Molecular modelling 
can be used to predict a suitable co-former to form co-crystals as well as crystal 
structures, bonding, and interactions between molecules. Molecular dynamics (MD) 
simulations are a well-established methodology capable of modelling the dynamic 
aspect of materials at the atomistic level. Various problems such as protein folding and 
drug discovery have successfully been studied using molecular dynamics [196]. 






Molecular modelling has been increasingly used in crystal engineering by a number of 
researchers. Research have been carried out to study the impact of choice of solvent 
on morphology of crystals such as by Song who investigated the crystal morphology 
of a nitroguanidine (NQ) via molecular dynamics simulations [198]. Hammond applied 
grid-based molecular methods for modelling solvent-dependent crystal growth 
morphology for aspirin [199] and Larsen studied the dehydration of hydrates based on 
molecular dynamics simulations and applied this approach to the dehydration of 
ampicillin trihydrate [200]. Tsangarides fabricated a pH sensitive photonic crystal 
sensor through photochemical patterning and demonstrated computational 
simulations of the sensor through a finite element modelling technique to analyse its 
optical properties [201]. Simulations can accurately predict many important molecular 
motions however, these simulations are poorly suited for systems where quantum 
effects are important, for example, such as when transition metal atoms are involved 
in binding [108].  
Yang studied the structural and computational insights into co-crystal interactions of 
antipyrine and aminophenazone and reported that density functional calculations 
indicated that H bond interactions in co-crystals [202]. Xiong studied the Molecular 
dynamic simulations on Dihydroxylammonium 5,5′-bistetrazole-1,1′-diolate - 
Cyclotrimethylenetrinitramine (TKX-50/RDX) co-crystal and reported that hydrogen 
bond and van der Waals force interactions exist in the co-crystal system and the 
hydrogen bonds are mainly derived from the hydrogen atom of TKX-50 with the oxygen 




The most important part of any simulation is the choice of forcefield which describes 
the approximate potential energy hypersurface on which nuclei of atoms move. Choice 
of forcefield will depend on the type of structure being examined [204]. This is because 
it is chosen for a group of systems rather than for individual structures. Forcefields are 
able to describe the potential energy surfaces of a group of molecules with reasonable 
accuracy [205]. Some forcefields aim for high accuracy for a limited set of elements, 
which enables excellent predictions of many molecular properties, while others aim for 
the widest coverage of the periodic table, with inevitably lower accuracy [206].  
A given forcefield usually contains several different interaction terms describing 






The components of a forcefield are as follows: 
• A list of forcefield types 
• A list of partial charges 
• Forcefield-typing rules 
• Functional forms for the components of the energy expression 
• Parameters for the function terms 
 
Many experimental properties such as vibrational frequencies, sublimation energies, 
and crystal structures can be reproduced with a forcefield [207], [208]. This is because 
the forcefield can reproduce relevant observables and include most of the quantum 
effects empirically.  
The forcefields commonly used for describing molecules use a combination of internal 
coordinates and terms such as bond distances, bond angles and torsions and external 
non-bond terms such as van der Waals, electrostatic and hydrogen bond interactions 
[209], [210]. 
 
The properties taken into consideration to define a particular forcefield type [211], [212] 
are as follows: 
 
• Element  
• Type of bonds  
• Number of other particles to which the given particle is bonded 
• The type of particles to which the given particle is bonded 
• Hybridization 
• Formal Charge 
 
Once the forcefield types have been defined for all the particles in the simulation, the 
Forcite parameter assignment engine can use them to locate the correct parameters 
for a given term in the energy expression [213]. 
 
2.8.1.1 Energy expressions 
 
An energy expression is created when the coordinates of a structure combines with a 
forcefield and describes the potential energy surface of a particular structure as a 





expressed as a sum of valence, cross-term, and nonbond interactions [215], [216] as 
shown in the equations below: 
 
Equation 1 - Total potential energy 
 
Σ𝑡𝑜𝑡𝑎𝑙 = Σvalence + Σcrossterm + Σnon−bond 
 
 
Equation 2 - Valence cross terms 
 
Σvalence = Σbond + Σangle + Σtorsion + Σinversion + Σ𝑈𝐵  
 
The energy of valence interactions is accounted for by diagonal terms, such as bond 
stretching, (Ebond), valence angle bending (Eangle), dihedral angle torsion (Etorsion), and 
inversion (Einversion) terms, which are part of nearly all forcefields for covalent systems. 
van der Waals, electrostatic and hydrogen bonding account for the energy of non-bond 
interactions [217]. A Urey-Bradley term (EUB) may be used to account for interactions 
between atom pairs involved in 1-3 configurations i.e atoms bonded to a common atom 
[218]. 
 
Equation 3 - Non-bond interactions 
 
Σ𝑛𝑜𝑛−𝑏𝑜𝑛𝑑 = ΣvdW + ΣCoulomb + Σhbond 
 
The energy of interactions between nonbonded atoms is accounted for by van der 
Waals (EvdW), electrostatic (ECoulomb), and hydrogen bond (Ehbond) terms [219]. 
 
2.8.1.2 Forcefield types 
 
The type of forcefield used gives an indication of the nature of the local microchemical 
environment of a given atom [220]. In this research the two different types of forcefield 










Condensed-phase optimized molecular potentials for atomistic simulation studies 
(COMPASS) is the first ab initio forcefield [221] that for a broad range of molecules 
and polymers, enables accurate and simultaneous prediction of: 
• gas-phase properties such as structural, conformational, and vibrational 
properties  
• condensed-phase properties such as the equation of state cohesive energies 
 
It is also the first high quality forcefield to establish parameters of organic and inorganic 
materials [221]. Various calculation methods have been used to validate the 
parameters for covalent molecules including extensive molecular dynamics 
simulations of liquids, crystals, and polymers [222], [223]. COMPASS forcefield had a 
broad coverage with organic molecules, small inorganic molecules and polymers [224] 
and can predict various properties such as molecular structures [225], crystal 
structures [226], equations of state [227], vibrational frequencies [228], conformation 





The analytic expressions used to represent COMPASS forcefield [232] is shown 
below. 
 


































Where ∑b, ∑θ, ∑Ø and ∑x, was the bond, angle, torsion, and out-of-plane angle co-
ordinates respectively. Among the cross-coupling terms, Fbb was the bond-bond, Fbθ 
was the bond-angle and FbØ was the bond torsion. r0 is the vdW radii and qi is the net 
partial charge of the atom.  
 
The COMPASS forcefield consists of quartic polynomials for bond stretching (Term 1) 
and angle bending (Term 2) and a three-term Fourier expansion for torsions (Term 3), 
the out-of-plane coordinate or inversion (Term 4), crossterms (Terms 5), coulombic or 
Electrostatic interaction between the atomic charges (term 6) and van der Waals 




The DREIDING forcefield is based on simple hybridization rules rather than on specific 
combinations of atoms. It does not generate parameters automatically in the way that 
other forcefields do. Instead, explicit parameters are derived by a rule-based approach 
[234]. 
 
DREIDING has a hydrogen bond term to describe interactions involving a hydrogen 
atom on very electronegative atoms such as -N or =O [235], [236]. The van der Waals 








are described by atomic monopoles and a distance dependent Coulombic term. 
Hydrogen bonding is described by an explicit Lennard-Jones 12-10 potential [234]. 
 
DREIDING forcefield allows reasonable predictions for a much larger number of 
structures, including those with novel combinations of elements and those for which 
there is little or no experimental data. The forcefield has good coverage for organic, 
biological and main-group inorganic molecules and can predict geometries [237], 
conformational energies [238], intermolecular binding energies [239] and crystal 
packing [240]. 
 
2.8.2 Geometry optimization 
 
Geometry optimization generates the optimal lowest energy structure of a molecule 
from a high energy starting state and proceeds as a set of single point energy 
calculations [241]. The optimization of a structure is completed in a two-step process; 
Energy evaluation and conformation adjustment. GO has been used for energy 
minimization of molecular clusters and complexes [242], large molecules [243], 




For any given conformation it is crucial to define and evaluate an energy expression 
[246]. Energy expressions includes external restraining terms that may need to be 





The conformation is adjusted to reduce the value of the energy expression [247]. A 
minimum energy structure may be found after one adjustment or may require more 
iterations, depending on the size of the structure, nature of the algorithm and the form 
of the energy expression [248]. The effectiveness of the optimization is evaluated by 
both the time needed to calculate the energy expression and the number of structural 






2.8.2.1 Line search  
 
The most common component of an optimizer is the ‘line search’ that modifies the 
coordinates to generate a new, lower energy structure [250]. An illustration of the line 
search is shown in the figure below. The derivative vector from the initial point a (x0, 
y0) defines the line search direction. Line search sums the one-dimensional 
optimization along a direction vector determined at each iteration [251].  
 
 




Extensive line searches are desirable because all the energy from one direction is 
extracted before moving on to the next [252]. The new derivatives are always 
perpendicular to the previous direction which produces a successful path to the 
minimum for surfaces that are approximately quadratic [253]. However, line searches 
are time consuming in terms of the number of function calculations that must be 
completed. The energy must be evaluated at 3-10 points to precisely locate the one-
dimensional minimum, and therefore extensive line searches are inefficient [254]. 
 
2.8.2.2 Optimization algorithm 
 
In mathematical terms the optimization of a molecular structure can be considered as 
optimization in a multidimensional space. The algorithm used for optimization in this 
research was the steepest descent algorithm [255]. The line search direction in the 
steepest descent algorithm is marked along the direction of the local downhill gradient. 
Each line search will produce a new direction perpendicular to the previous gradient 





The steepest descents method is often used when the gradients are large, and the 
configurations are far from the minimum which is usually the case for the initial 
relaxation for built models. Convergence is slow near the minimum as the gradient 
approaches zero, but the method is extremely robust [257], even for systems that are 
far from harmonic. Steepest descent method is most likely to generate the true low-
energy structure, regardless of what the function is or where the process begins [256].  
 
2.8.3 Dynamics theory  
 
All equations were taken from the BIOVIA Materials studio handbook [258]. 
 
Molecular dynamics solves Newton's equation of motion which states that the time rate 
of change of the momentum of a body is equal in both magnitude and direction to the 
force imposed on it [259], [260]. Once the initial coordinates and velocities are known, 
the coordinates and velocities later can be determined. 
 
Equation 5 - Newton's equation of motion 
 
Ϝί (t) = m ί a ί (t) 
 
where F ί is the force, m ί is the mass, and a ί is the acceleration of atom ί [261]. 
 
2.8.3.1 Velocity varlet integrator 
 
Molecular dynamics is generally utilized on large models. Energy evaluation therefore 
is time consuming and requires large computer memory. Energy conservation is also 
crucial to generate the correct statistical ensemble Therefore, a good integrator for 
molecular simulations is required [262].  
The requirements for a good integrator used for molecular simulations are that it 
should: 
 
• Be fast and preferably only require one energy evaluation per time step. 
• Require as little computer memory as possible. 





• Show good conservation of energy. 
 
The most widely used method in molecular dynamics to integrate the equations of 
motion are variations of the Verlet algorithm [263]. The advantage of using this 
algorithm is that it requires only one energy evaluation per step, require moderate 
memory, and allows for a relatively large time step to be used [264]. 
 
Verlet velocity integrator 
 
 
Equation 6 - The Verlet velocity algorithm 
 










𝑣(𝑡 + ∆𝑡) = 𝑣(𝑡) +
1
2
∆𝑡[𝑎(𝑡) + 𝑎(𝑡 + ∆𝑡)] 
 
 





2.8.3.2 Statistical ensembles  
 
Although using Newton’s equation of motion allows the constant energy surface to be 
explored, it is not a replica of the natural phenomenon of the system when exposed to 
external pressure or temperature. Under these conditions, extended forms of 
molecular dynamics are required to study the system.  
There are several methods available for controlling temperature and pressure i.e. NVT, 
NVE, NPH and NPT [265]. Depending on which state variables are kept fixed - such 
as number of particles, volume, temperature, pressure and energy - different statistical 
ensembles can be generated [266].  










The NVT ensemble, also known as the canonical ensemble, keeps the number of 
particles, volume, and temperature constant [267]. The temperature control method is 
based on the Nosé-Hoover thermostat that is used for performing constant-
temperature dynamics that produces true canonical ensembles in both coordinate 
space and momentum space [268].  
 
Equation 7 - NVT Ensemble 
 




























Qi are the thermostat fictitious masses 
ξi are the thermostat degrees of freedom 
 
 
Nosé-Hoover dynamics adds an additional degree of freedom to the structure which 
represents the interaction of the structure with the heat bath [269].  
 
















where φ is the interaction potential and ζ and ln S play the role of the velocity and 
position of the extra degree of freedom, with associated mass Q. 
 
NVE Ensemble  
 
NVE Ensemble, also known as the microcanonical ensemble, is a constant-energy, 





without any temperature and pressure control. When this ensemble is generated, the 
energy is conserved. NVE conditions are used during the equilibrium phase of the 
dynamics.  
 
Equation 9 - NVE Ensemble 
 






















2.8.3.3 Forcite Anneal 
 
 
The Forcite Anneal task can be used to investigate conformational space for low 
energy structures by periodically increasing and then decreasing the temperature of a 
structure or model [270]. This avoids restricting the structure in a conformation that 
represents a local energy minimum. The forcite anneal task consists of dynamics 
calculation with a change in temperature to follow a specific anneal schedule followed 





Particle velocities are assigned at random from a Maxwell-Boltzmann distribution at 
the start of a simulation and an integration is then performed in the microcanonical 
ensemble [271]. This would show a decline in temperature as some of the kinetic 
energy is transferred to potential energy. To ensure a simulation is at equilibrium, it is 
important to run it for moderately long time before analysis. In most cases, a thermostat 
can facilitate an equilibrium [272]. A system at equilibrium can be defined by plotting 
the energy or temperature against time and determining whether the numbers fluctuate 







2.9 Chapter conclusion 
 
This chapter introduced the pharmaceutical drugs, co-crystals and polymers used in 
the research. The current approached to improve the dissolution of poorly soluble 
drugs, the challenges in formulation and solution to overcome these issues were 
discussed.  The detailed explanation and several key issues about co-crystals were 
presented, including co-crystal design mechanisms, co-former selection, different 
types of co-crystal formation methods, co-crystal characterization techniques and co-
crystal physicochemical properties. The key problem of co-crystals during dissolution, 
solution media phase transformation, was discussed as well as methods to overcome 
the problems. Some information about the materials that used in this study were 
introduced, including FFA, FFA co-crystals, NIC, TP, PEG, PVP and PVP-VA. Finally, 
molecular modelling and molecular dynamics were discussed including the different 
types of forcefields, geometry optimisation methods and the different algorithms used 



















Chapter 3 – Materials and Methods 
 
3.1 Chapter overview 
 
This chapter presents materials and analytical methods used in the current research. 
All materials used are listen in detail, including the name, level of purity and the 
manufacturers. Analytical methods including ATR-FTIR, DSC, XRPD, Raman, Non-
contact AFM, SEM and NMR are fully described. These methods were used to identify 
the co-crystals and characterise their physicochemical properties. ATR-FTIR, DSC, 
XRPD and Raman were used to perform qualitative analysis of formed samples, and 
the Raman spectrometer was also used for quantitative analysis of the phase transition 
of samples during the dissolution process. SEM and non-contact AFM were used to 
characterize the morphology of solid compacts. NMR was used to look at the 
interaction of the molecules in solution. Properties such as non-bond energies, 
hydrogen bonding, radial distribution function and mean square displacement were 




All materials were used as received, without further processing. The details of 
materials were presented in the table below. 
 
Table 1 - List of materials used in this study 
 
Materials Formula Purity/grade Manufacturer 
Flufenamic Acid C14H10F3NO2 97% 
Sigma-Aldrich Company 





Ltd.,Dorset , UK 
Nicotinamide C6H6N2O ≥99.5% 
Sigma-Aldrich Company 
Ltd., Dorset, UK 







Methanol CH3OH HPLC grade 
Fisher Scientific 
Loughborough, U.K. 
Ethanol CH3CH2OH Lab grade 
Fisher Scientific 
Loughborough, U.K. 
Acetonitrile CH3CN HPLC grade 
Fisher Scientific 
Loughborough, U.K. 
Chloroform-d CDCl3 99.8% 
Cambridge Isotope 











Ethyl acetate  C4H8O2 HPLC grade  
Fisher Scientific 
Loughborough, U.K. 
PEG 4000 C2nH4n+2On+1 - 
Sigma-Aldrich Company 
Ltd., Dorset, UK 












3.3.1 Preparation and synthesis 
 
3.3.1.1 Co-crystal synthesis 
 
FFA-TP co-crystals were synthesized by cooling crystallization method. A 1:1 molar 
ratio of FFA and TP was completed dissolved in a co-solvent of (7:3) acetonitrile and 
water with stirring at 70°C. After the solid had completed dissolved, the solution was 
placed into an ice bath until the crystals had separated out from the solution. The 





filter papers with 100mm qualitative circles. A physical mixture of FFA-TP was 
produced by mixing thoroughly a 1:1 ratio of FFA and TP. Single co-crystals of FFA-
TP were synthesised using the remaining solution from co-crystal synthesis. A film 
containing small holes was used to cover the solution and the solution was left in a 
fume cabinet over a period of 3 days for the single co-crystals to form. The co-crystals, 
single co-crystals and the physical mixtures were characterized and validated using 
Different scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR) 
and X-ray powder diffraction (XRPD). 
 
The FFA-NIC Co-crystal was prepared by using the solvent evaporation method. 1:1 
equimolar mixture of FFA and NIC was completely dissolved in acetonitrile with stirring 
at 70°C. The solution was placed in a fume cabinet overnight for solvent evaporation. 
A physical mixture of FFA-NIC was produced by mixing thoroughly a 1:1 ratio of FFA 
and NIC. Single co-crystals of FFA-NIC CO were produced by solvent evaporation 
method by dissolving a 1:1 ratio of FFA and NIC in a co-solvent of (7:3) acetonitrile 
and water. FFA-NIC CO was added as seeds into the solution and the solution was 
then covered with a film containing small holes and was left to evaporate over a period 
of 3 days.  
 
CBZ-NIC Co-crystals were prepared by the cooling crystallisation method. A 1:1 molar 
ratio mixture of CBZ III and NIC was completely dissolved in Ethyl Acetate (EtOAc) by 
stirring at 50°C. The solution was put in an ice bath for two hours and the suspension 
was then filtered through 0.45 μm filters (thermo Scientific Nalgene) to collect the solid 
residue of CBZ-NIC co-crystals. A physical mixture of CBZ-NIC was prepared by 
thoroughly mixing a 1:1 ratio of CBZ and NIC. Single co-crystals of CBZ-NIC CO were 
produced by solvent evaporation method. A 1:1 ratio of CBZ III and NIC was dissolved 
completely in Ethyl Acetate at 50˚C. The solution was then covered with a film 
containing small holes and was left to evaporate over a period of 5 days.                                                                          
 
3.3.1.2 Single co-crystals synthesis 
 
The FFA-NIC cocrystal powders were added as seeds to newly prepared FFA and NIC 
cosolvent solution. The solution was then covered with a film containing small holes 
and was left to evaporate over a period of three days. FFA-NIC single co-crystals were 





Single co-crystals of FFA-TP were directly synthesised using the acetonitrile-water 
cosolvent. A film containing small holes was used to cover the solution which was left 
in a fume cabinet over a period of three days for formation of the single co-crystals. 
FFA-TP single co-crystals were harvested by filtration of the mother solutions.   
Single co-crystals of CBZ-NIC were produced by dissolving 1:1 ratio of CBZ and NIC 
in ethyl acetate. A film containing small holes was used to cover the solution which 
was left in a fume cabinet over a period of three days for the single co-crystals to form. 
CBZ-NIC single co-crystals were harvested by filtration of the mother solution. 
 
3.3.2 Analytical techniques 
 
3.3.2.1 Attenuated total reflection Fourier transform infrared (ATR-FTIR) 
 
Infrared Spectroscopy is the analysis of infrared light interacting with a molecule and 
can be analysed in three ways by measuring the absorption, emission, and reflection 
[274]. The 2D infra-red spectra contains information on the molecular structure of 
materials and can be used to find the functional groups of molecules based on a 
sequence of laser IR pulses [275]. 
ATR-FTIR can provide information on identity of unknown materials, determine the 
quality or consistency of a sample and determine the components in a mixture. ATR-
FTIR can work with weak signals, provide high spectral resolutions, results can be 
acquired quickly with high spectral accuracy [276]. ATR-FTIR consists of a Source, 
Interferometer, Sample compartment and a detector. Infrared energy is emitted from 
the source and enters the interferometer. Molecules absorb specific frequencies of 
infra-red light that are characteristic to their structure [277]. Sample molecules, when 
exposed to infra-red radiation will absorb radiation of specific wavelengths which alters 
the dipole moment. This causes the energy levels of the sample molecules to transfer 
from ‘ground state’ to ‘excited state’. The change in the dipole moment and transition 
in the energy levels is related to the intensity of the absorption peaks [278]. The 2D 
infra-red spectra contain information on the molecular structure of materials and can 
be used to find the functional groups of molecules based on a sequence of laser IR 
pulses. The method requires a very small amount of a sample it is fast and produces 






Infra-red spectrums are created by passing a beam of infra-red light through an 
interferometer, then through the sample. Specific frequencies of energy that are 
uniquely characteristic to the sample are absorbed and the beam passes to the 
detector. The detector measures the interferogram signal and is sent to the computer 
for the FTIR spectrum to be produced. The resulting spectrum creates a fingerprint of 
the sample, representing the molecular absorption and transmission [280]. Different 
materials have different combinations of atoms therefore no two compounds produce 
the same FTIR spectrum.  
In this experiment, a Perkin Elmer FTIR was used. The resolution was set at 2, sample 
scan time was set at 30 minutes and the wavelength was set to produce from 4000-
400nm. 
 
3.3.2.2 Differential scanning calorimetry (DSC) 
 
DSC is a thermo-analytical technique which measures the difference in the amount of 
heat required to increase the temperature of a sample and a reference that is 
measured as a function of temperature. The sample holder temperature increases 
linearly as a function of time [281]. The temperatures of the sample and reference are 
maintained throughout the experiment. When a sample undergoes phase transition 
the amount of heat required to maintain the temperature varies in comparison to the 
reference. Whether a high or a low temperature required is dependent on the type of 
process such as exothermic or endothermic [282]. By observing the difference in heat 
flow between the sample and reference, differential scanning calorimeters are able to 
measure the amount of heat absorbed or released during such transitions. A number 
of characteristic properties of samples can be measured using DSC such as 
crystallization and glass transition temperatures [233]. 
The main applications of DSC include the phase transition characterization, such as 
melting point [117], glass transition [283], determination of crystallinity [284], kinetic 
studies [285], drug transformation and physical stability tests [286], material 
fingerprinting and purity control [287]. DSC is the most often used thermal analysis 
method, mainly because of its speed, simplicity, and convenience.  
In this experiment a Perkin Elmer differential scanning calorimetry was used. Samples 
weighing between 3-12mg were weighed using an analytical balance in aluminium 





samples were heated at a constant rate of 20˚C/min with the temperature ranging was 
from 50°C to 320°C.  
 
3.3.2.3 X-ray powder diffraction (XRPD) 
 
Single co-crystal and powder diffraction data contain the same structural information, 
except this information is distributed in three-dimensional (3D) space in the single co-
crystal diffraction pattern, and is compressed into one dimension in the powder 
diffraction pattern [288]. It is important to fully characterise an API to define its crystal 
structure [289]. Different crystal structures comprise of distinct XRD patterns known as 
the ‘fingerprint region’ which allows for identification of different APIs, solvates, salts 
and co-crystals [290]. The structure determination shows the chemical composition of 
the crystal and provides geometric information about the molecules, the interplanar 
distances and the geometries of intermolecular interactions [291]. 
 
X-ray powder diffraction (XRPD) is a rapid analytical technique used for phase 
identification of a crystalline material and can provide information on unit cell 
dimensions [292].  
 In XRPD, the crystalline atoms cause a beam of incident X-rays to diffract in many 
specific directions. The angles and intensities of these diffracted beams can be 
measured to produce a 3D picture of the density of the electrons within the crystal. The 
mean position of the atoms, their chemical bonds and the states of disorder can be 
calculated from this 3D image [293]. The regular array of atoms in the crystals scatter 
the X-ray. An X-ray striking the electron produces an array of spherical waves in a 
phenomenon known as elastic scattering. Although these waves cancel one another 
out in most direction through destructive interference, they add constructively in a few 
directions, determined by Bragg’s Law shown below.  
  
Equation 10 - Bragg’s Law 
2dsinθ = nλ  
Here d is the spacing between diffracting planes, θ is the incident angle, n is any 
integer, and λ is the wavelength of the beam. These specific directions appear as 





from an electromagnetic wave impacting on a regular array of scatters. These 
diffracted X-rays are then detected, processed, and counted. By scanning the sample 
through a range of 2θ angles, all possible diffraction directions of the lattice should be 
attained due to the random orientation of the powdered material. Conversion of the 
diffraction peaks to d-spacings allows identification of the mineral because each 
mineral has a set of unique d-spacings. This is achieved by comparison of d-spacings 
with standard reference patterns [294].  
Single co-crystal and powder diffraction data contain the same structural information, 
except this information is distributed in three-dimensional (3D) space in the single co-
crystal diffraction pattern, and is compressed into one dimension in the powder 
diffraction pattern [288].  
A D2 PHASER diffractometer (Bruker U.K. Limited, Coventry, UK) of the PXRD 
provided the results from 5° to 35° at a scanning rate of 0.3° (2θ) min−1. Cu Kβ was 
the radiation source, and it was used at 30 kV, 10 mA. 
 
3.3.2.4 Raman Spectroscopy 
 
Raman spectroscopy has been effectively used in many studies of polymorphs, co-
crystals, salts and solvates and involves their identification, structural characterisation, 
phase transformations and quantification in mixtures [295]–[297]. Raman 
spectroscopy is used to observe vibrational, rotational and other low-frequency modes 
in systems and provides information about molecular vibrations that can be used for 
sample identification and quantitation. It relies on Raman scattering of monochromatic 
light, usually from a laser in the visible, near-infrared or near-ultraviolet ranges on a 
sample and detecting the scattered light [298]. The Raman effect occurs when 
electromagnetic radiation affects a molecule and interacts with the polarisable electron 
density and the bonds of the molecule. For the spontaneous Raman effect, which is a 
form of inelastic light scattering, a photon excites the molecule from the ground state 
to a virtual energy state for a short period of time shown in Figure 11.  
When the molecule relaxes it emits a photo and it returns to a different rotation or 
vibration state. The resulting scattered photon which is “emitted” or “scatted” can be of 
either higher – Stokes scattering- or lower – anti-stokes scattering - energy than the 





would be in a different rotational or vibrational state in comparison to the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
original molecule, before interacting with the incoming photon. 
The difference in energy between the original state and this final state gives information 
about the vibration modes in the system, due to the vibration information being specific 
to the chemical bonds and symmetry of molecules. It therefore provides a fingerprint 
by which the molecule can be identified [300]. Raman technique is used for providing 
both structural and electronic insight into species of interest. Raman spectroscopy can 
be used for both qualitative and quantitative applications  [295].  Raman bands are 
inherently sharper than their infrared counterparts; isolated bands are often present in 
the spectrum for more straightforward quantitative analysis. Raman spectroscopy has 
been used for the structure determination of nanoparticles [301], polymers [302], [303] 





Raman spectroscopy analysis is regarded as non-destructive, although lengthy 
irradiation with ultraviolet (UV) or visible light lasers in some samples can cause 
photodecomposition. As the Raman spectrum is acquired from a very small area, 
special care must be taken to make it representative for the whole material [299], [306].  
In this experiment, En Spectr R532 Raman spectroscopy was used to study single co-
crystals before and after dissolution in distilled water and water containing various 
polymers. The samples were placed in the sample holder. Single crystals were 
scanned at exposure time = 200ms and number of frames to collect = 600. Co-crystals 
were scanned at exposure time = 200ms and number of frames to collect = 100. 
 





3.3.2.5 Non-contact Atomic force Microscopy  
 
Atomic force microscopy (AFM) was invented in the early 1980s and has since had a 
major impact on the characterisation of surface structures. Increasingly, however, the 
method is being applied in looking at the topographic layer of crystals. AFM operate 
by measuring the force between a probe – a sharp tip with 15-40nm end radius- and a 
sample [307]. The probe is bought into close proximity of the sample surface and then 
scanned in a systematic manner. An image is acquired by measuring the vertical and 
lateral deflections of the cantilever by using an optical lever that works by reflecting a 
laser beam off the cantilever [308]. The reflected laser beam strikes a position-
sensitive photo-detector that indicates the position of the laser spot on the detector 
and therefore the angular deflections of the cantilever. Direct contact of the tip with 
sample surfaces may damage the sample in some cases, therefore non-contact AFM 
is used. The non-contact forces the cantilever oscillation at resonance frequency [309]. 
The oscillating probe will be influenced by the close surface and therefore due to van 
der Waals attractive forces, produces a frequency shift in the resonance frequency. 
The signals recorded in non-contact mode are therefore related to the variation 
between cantilever resonance frequency and free oscillation of the system. This gives 
an estimate of the tip to sample interaction forces intensities [310].  
The images produced by non-contact AFM may be determined by frequency variations 
related to fluctuations in frequency shift as a direct signal or as a feedback-loop signal. 
As a consequence, resonance frequency and oscillation amplitude both corresponds 
to the surface image formation [309]. Moreover, in order to minimize the attractive 
forces onto the tip close to the surface, the spring constant used in non-contact mode 
is greater than in contact mode. In recent years, atomic force microscopy has been 
used extensively to study various aspects of molecular crystals such as the mechanism 
of crystal growth [311] and additive-induced crystal growth inhibition [312].  
The advantage of using AFM over other conventional microscopy techniques is that 
AFMs probe the sample and make measurements in three dimensions, x, y, and z, 
therefore enabling the presentation of three-dimensional images of a sample surface 
[313]. Major drawbacks of non-contact mode concern low lateral resolution and 
constrained use of the tip in air environment [314]. The operation of AFM is shown in 











3.3.2.6 Scanning electron microscopy 
 
A scanning electron microscope (SEM) scans samples by scanning it with a focused 
beam which produces images.  
The main SEM components include: 
• Source of electrons 
• Column down which electrons travel with electromagnetic lenses 
• Electron detector 
• Sample chamber 
• Computer and display to view the images 
Electrons are produced at the top of the column, accelerated down and passed through 
a combination of lenses and apertures to produce a focused beam of electrons which 
hits the surface of the sample [315]. The electrons would interact with atoms in the 
sample, that produces various measurable signals containing information about the 
sample’s surface topography and composition. The electron beam is generally 
scanned in a raster scan pattern, and the beam’s position is combined with the 
detected signal to produce an image [316].  
In this study, SEM micrographs were photographed by a ZEISS EVO HD 15 scanning 





were mounted with Agar Scientific G3347N carbon adhesive tab on Agar Scientific 
G301 0.5” aluminium specimen stub (Agar Scientific Ltd., Stansted, UK) and 
photographed at a voltage of 10.00 kV. The manual sputter coating S150B was used 
for gold sputtering of SEM samples. 
 
3.3.2.7 Nuclear Magnetic Resonance  
 
NMR is a spectroscopy absorbs and re-emits electromagnet radiation in a magnate 
field which is used to study the chemical, physical and structural information of 
molecule in solution and to study molecular physics and crystals as well as non-
crystalline materials [317].  
The theory of NMR involves three consecutive steps [318]:  
• The alignment of the magnetic nuclear spins in an applied, constant magnetic 
field.  
• The distress of this alignment of the nuclear spins by a weak oscillating 
magnetic field known as a radio-frequency (RF) pulse.  
• The NMR signal is detected during or after the RF pulse, due to the voltage 
being induced in a detection coil by precession of the nuclear spins. 
All nuclei present in a molecule are charged and molecules with an odd number of 
electrons have a spin which creates a magnetic field [319].  A proton and neutron will 
have lower energy when their spins are parallel which causes an energy transfer to 
take place from a ground state to an excited state by absorbing radio frequency. The 
energy is then emitted when the excited state of the nuclei returns to its ground state 
[320]. The emitted frequency is converted to the chemical shift in ppm in an NMR 
spectrum. For proton NMR, the reference molecule is tetramethyl silane (TMS). 
A change in the chemical shift occurs when the electron density around the nucleus is 
altered [321]. A high electron density around the nucleus leads to the shielding of the 
nucleus and causes a low chemical shift and triggers the signal to move up-field and 







Equation 11 - NMR chemical shift 
 
𝛿 =  (
𝐻𝑟𝑒𝑓  −  𝐻𝑠𝑢𝑏 
𝐻𝑚𝑎𝑐ℎ𝑖𝑛𝑒
) × 106 
 
where Href = is the resonance frequency of the reference, Hsub = is the resonance 
frequency of the substance, and Hmachine = is the operating frequency of the 
spectrometer. 
DOSY results are displayed as 2D spectra with the NMR chemical shift on the 
horizontal axis and the derived diffusion coefficients on the vertical axis.  
An NMR spectrum gives the following information: 
• The number of peaks indicate the different types of nucleus present. 
• The location of the peak indicates the type of nucleus its chemical environment. 
• The relative areas of the peaks give the relative number of each type of 
nucleus. 
• Disruption in the peak, indicates that affected nuclei 
NMR spectroscopy has been successfully used to study molecular structures of small 
molecules [322], characterise protein-ligand interactions [323] and in polymorph and 
co-crystal investigation [324] and polymer characterisation [325].  
Diffusion-ordered spectroscopy (DOSY) 
Diffusion‐ordered spectroscopy (DOSY) is used to analyse a mixture based on pulsed 
field gradient spin (PFGSE) or stimulated (PFGSTE) echo measurements. Diffusion 
coefficient is characteristic of a given molecule, therefore, the NMR signals from 
species of different sizes can be easily distinguished [326]. One of the earliest methods 
of determining diffusion coefficient was to use the Stokes-Einstein equation. However, 
a more acceptable method now is by Wilke and Chang who have suggested a more 














Where D is the diffusion coefficient, ϕs is a constant characteristic of a solvent; Ms is 
the molar mass of the solvent; T is the absolute temperature; ηs is the viscosity of the 
solvent; VD is the LeBas molar volume. 
Both 1H NMR and DOSY-NMR measurements for each of the samples were carried 
with JEOL ECZ 600R series FT-NMR Spectrometer (JEOL Ltd, Tokyo, Japan). 1H 
proton spectra were achieved after 64 scans, with a relaxation delay of 7s at a 
controlled temperature of 25°C. 1H NMR spectra chemical shifts were analysed using 
Mnova 14.2.0 by Mestrelab. For DOSY-NMR measurements, stimulated spin echo 
with bipolar gradient pulses was employed to determine the molecule self-diffusion 
coefficient. DOSY spectra were achieved after 32 scans, with a relaxation delay of 6s, 
at a controlled temperature of 25°C. The gradient was from 0.3 – 300 mT/m with 14 
gradual increments. The spectra were analysed using GNAT (General NMR Analysis 
Toolbox) and the diffusion coefficient was found from the table generated. DOSY 
results are displayed as 2D spectra with the NMR chemical shift on the horizontal axis 
and the derived diffusion coefficients on the vertical axis.  
 
3.3.3 Calculating molecular dynamic properties  
 
All equations were taken from the BIOVIA Materials studio handbook [258]. 
Binding energy ∆Ebind can accurately reflect the features of the components to study 
the interactions between the crystal surface and polymer because an interaction 
system can be formed between a polymer and crystal surface after the MD simulation. 
The molecular interaction can be evaluated by a single point total energy of each 








Equation 13 - Binding energy 
 
∆𝐸𝑏𝑖𝑛𝑑 = 𝐸𝑠𝑦𝑠𝑡𝑒𝑚 − (𝐸𝑝𝑜𝑙𝑦𝑚𝑒𝑟 − 𝐸𝑠𝑢𝑟𝑓𝑎𝑐𝑒) 
 
Where 𝐸𝑠𝑦𝑠𝑡𝑒𝑚 is the total energy of the bonded polymer and crystal surface system, 
𝐸𝑝𝑜𝑙𝑦𝑚𝑒𝑟 is the energy of the polymer and 𝐸𝑠𝑢𝑟𝑓𝑎𝑐𝑒  is the energy of the surface. 
 
 
3.3.3.1 Non-bond energies 
 
 
Electrostatic (Coulombic) and van der Waals interactions are referred to collectively as 
non-bond interactions and are usually divided by the forcefield.  
Electrostatic interactions 
The electrostatic interaction arises from the unequal distribution of charge in a 
molecule which can be modelled by placing point charges at each atomic position 
using a forcefield [327]. Electrostatic interactions can be calculated by using the 
equation below. 







where 𝜖0 is the permittivity of free space, 𝑞𝑖 are atomic charges, and 𝑟𝑖𝑗 is the 
distance between i and j. 
Van der Waals interactions 
Van der Waals interactions consists of all interactions between the atoms no covered 
by the electrostatic interactions [328]. This includes the dispersion, repulsion, and 
induction forces as well as others. Correlation between electrons in different atoms 
leads to dispersion interactions which attracts the atoms towards each other due to the 
reduced energy [329]. The overlapping of two electron clouds of two different atoms 
leads to repulsion forces. The distortion of the charge distribution of an atom or 





Van der Waals forces shows large positive values of atomic repulsion at small 
distances and at large distances the dispersion interaction gives small negative values. 
This behaviour can be shown by the Lennard-Jones potential [331], shown below. 




















3.3.3.2 Hydrogen bonding  
 
Hydrogen bonding is a dipole-dipole attraction between molecules that results from the 
attractive force between a hydrogen atom covalently bonded to a very electronegative 
atom such as a N, O, or F atom and another very electronegative atom [332].  
Hydrogen bonds can occur between separate molecules known as intermolecular 
bonding or can occur among parts of the same molecule known as intramolecular 
bonding [333]. They are stronger than Van der Waals interactions and weaker than 
covalent bonds. The functional form of the hydrogen bond potential is shown below. 




4]𝑐𝑜𝑠4(𝜃 − 𝜃0)𝑆𝑊(𝑅𝐷−𝐴) 
 
where ɛ is a weight or strength of the hydrogen bond interaction and σ is related to 
the distance R0 at minimal potential. 
Hydrogen bonds are the crucial to many phenomena, including molecular recognition 
[334], [335] and drug binding [336]. It also plays an important role in the structure of 







3.3.3.3 Radial distribution function 
 
Radial distribution function, also known as the pair correlation function, measures the 
probability that, given the existence of an atom at the origin of a random reference 
frame, there will be an atom with its center positioned in a spherical shell of minute 
thickness at a distance, r, from the reference atom [339]. This theory also states that 
the atom at the origin and the atom at distance r may be of different chemical types. 
The form for radial distribution function is shown below. 
 













Where 𝑥𝛼 is the mole fraction of chemical type α, 𝑁𝛼 is the number of atoms of chemical 
type α, N is the total number of atoms, and ρ is the overall number density.  
 
Radial distribution function has been applied in structural investigations of local 
packing structures of both solids and liquids [340], in studying hydrogen bonding [341] 
and in statistical mechanical theories of liquids and mixtures [342].   
 
3.3.3.4 Mean square displacement 
 
Mean square displacement (MSD) analysis determines the average displacement of 
particles followed over time. It can be helpful in determining whether the particle is 
freely diffusing, being transported, or bound [343]. MSD can also estimate the 
parameters of movement i.e diffusion coefficient for freely moving molecules [344], 
[345]. MSD can be acquired from particle positions in an MD simulation. 
 
In an equilibrium ensemble, the mean squared displacement must be independent of 
the time t, and can be averaged out, giving the mean square displacement over an 




















= 〈[𝑟(𝑡 − ∆𝑡) − 𝑟(𝑡)]2〉 
 
 




3.4 Chapter conclusion 
 
This chapter presented the materials, preparation and synthesis, analytical techniques 
and molecular dynamic properties used in this study. The name, formula, purity, and 
manufacturer of materials were presented followed by the working principle, 
application, instrumental setting, operation procedure and instrumental models of 
analytical techniques such as ATR-FTIR, DSC, XRPD, Raman spectroscopy, non-
contact AFM, SEM and NMR. Finally, the molecular dynamic calculations to calculate 
properties such as non-bond energies, hydrogen bonding, radial distribution function 












Chapter 4 – Characterisation of 
Samples 
 
4.1 Chapter Overview 
 
In this chapter, FFA-NIC CO, FFA-TP CO and CBZ-NIC CO were prepared by using 
solvent evaporation and cooling crystallization methods. More detail on the preparation 
methods is given in Chapter 3. Different analytical techniques such as ATR-FTIR and 
XRPD were used to confirm the formation of co-crystals by comparing the spectra of 
individual components (FFA I, NIC, TP and CBZ) to the co-crystals FFA-NIC CO, FFA-
TP CO and CBZ-NIC CO and physical mixtures to identify new chemical 
peaks.  Physical mixtures are constituent substances not chemically combined. DSC 
was used to check whether a change in the melting point had occurred. The results of 
these analytical techniques show that all co-crystals were successfully synthesized. 
 
4.2 Materials and Methods 
 
FFA I, NIC, TP, CBZ III, ethyl acetate, acetonitrile and double distilled water were used 
in this chapter and detailed introduction of this materials can be found in chapter 3.  
FFA-NIC CO and CBZ-NIC CO were formed by solvent evaporation method and FFA-
TP CO was formed by cooling crystallization method. ATR-FTIR, DSC, XRPD and 
Raman have been used to characterize the formation of co-crystals. Details of co-




















FFA-TP co-crystals are formed via hydrogen bonding. The carboxamide functional 
groups from both the FFA and TP provide hydrogen bonding donors and acceptors. 
The FTIR spectrum for FFA contains peaks at 3322 cm-1 and 1651 cm-1 which 
corresponds to bonds N-H stretch and C=O stretch forming the carboxamide functional 
group. The IR spectrum of the co-crystal contains two peaks at 3282 cm-1 and 3070 
cm-1 corresponding to the N-H groups. 
 The spectrum shows a shift in the N-H bond contained in the FFA from 3322 cm-1 to 
3282 cm-1 and a shift of the N-H in TP from 3119 cm-1 to 3070 cm-1. Further two shifts 
are also observed at 1651 cm-1 and 1657 cm-1 corresponding to the C=O group found 
in TP and FFA respectively. The table detailing the bonds and the frequency shifts can 
be found in Appendices A1.  Therefore, the shifts of the IR spectrum suggest that FFA 
and TP are reformed in a new phase. The physical mixture shows a similar trend as 
the co-crystal, but the spectrum is very similar to the FFA and TP suggesting no new 
functional groups have been formed. FFA spectrum contains a peak at 1330 cm-1 
corresponding to the bond C-F. This bond is found in the physical mixture but has 
shifted in the co-crystal. All these changes that occurred in the spectrum indicates an 





crystal contains the same peak as the co-crystal indicating the same structure for both. 
A list of the peak positions and assignments can be found in the Appendices Table 1 
under ATR-FTIR. 
 




As shown in the figure above and Table 2 (Appendices), due to the formation of FFA-
NIC Co-crystal, the NH bond in FFA has shifted to a higher frequency from 3322 cm-1 
to 3397 cm-1 which indicates the formation of the carboxamide group. FFA contains a 
shift from 1651 cm-1 to 1664 cm-1 that attributes to the C=O stretching which suggests 
that the carbonyl group is taking part in the formation of hydrogen bond in the co-
crystal. A shift is seen in the NIC from 3362 cm-1 to 3397 cm-1 contributing to the N-H 
group and a shift from 1680 cm-1 to 1664 cm-1 corresponding to the C=O bond 
(Appendices A1). This suggests that FFA and NIC have been reformed in a new phase. 
The single co-crystal contains the same peak as the co-crystal indicating the same 
















CBZ-NIC co-crystals are formed via hydrogen bonds in which the carboxamide groups 
from both CBZ and NIC provide hydrogen bonding donors and acceptors. The spectra 
of CBZ-NIC co-crystals is different from those of CBZ and NIC, suggesting that both 
molecules are present in a new phase. CBZ’s carboxamide N-H and C=O stretching 
frequencies shifted to 3448 and 1683 cm-1 respectively. While NIC’s N-H stretching 
frequency shifted to 3395 cm-1 and the C=O stretching shifted to 1659 cm-1 
(Appendices A1). The spectrum of the CBZ-NIC physical mixture peaked at 3464 and 
1676 cm-1 due to the presence of CBZ III.  A summary of IR peak identities for CBZ III, 






















Table 2 - DSC onset and peak values of FFA-TP 
 
Sample Onset (˚C) Peak (˚C) 
FFA 134.88 141.11 
TP 272.25 277.88 
FFA-TP PM 128.24, 187.53 139.75, 191.15 
FFA-TP CO 188.56 194.64 
FFA-TP SC 188.35 193.99 
 
The DSC curve shows that FFA melted at around 134.88°C and TP melted at around 
272.25°C. FFA-TP physical mixture exhibited two major thermal events, with the first 
endothermic-exothermic peak at 128.24˚C due to the melting of FFA and the co-
crystallisation of FFA-TP co-crystals. The later endothermic peak, at around 187.53oC, 





the physical mixture had converted to a co-crystal. For FFA-TP co-crystal, a single, 
sharp, endothermic peak was exhibited at 188.56°C. The melting point of the co-crystal 
also differs from the single components suggesting the formation of a new compound 








Table 3 – DSC onset and peak values of FFA-NIC 
 
Sample Onset (˚C) Peak (˚C) 
FFA 134.88 141.11 
NIC 129.62 135.08 
FFA-NIC PM 126.10, 157.87 130.14, 161.86 
FFA-NIC CO 156.33 159.31 
FFA-NIC SC 156.43 158.09 
 
A DSC curve of pure NIC had a single peak at 129.62C which contributes to the 





endothermic transition peak at 156.33C resulting from the pure FFA-NIC Co-crystal. 
FFA-NIC Co-crystal had an obvious difference thermal behavior compared with pure 
FFA I, NIC and FFA-NIC physical mixture, demonstrating that FFA-NIC CO is a new 
compound. The findings are consistent with previous results published by Lazlo Fabian 
[155]. The DSC curve of FFA-NIC PM had a complex thermal behavior that showed 
two endothermic peaks compared with pure FFA and NIC. The first peak was due to 
the melting of NIC, and the later endothermic peak at 157.87C is due to the melting 
of FFA-NIC CO. The results obtained from DSC of FFA-NIC CO agree with the results 
of Raman and FTIR. The single co-crystals also showed a similar thermal behaviour 








Table 4 - DSC onset and peak values of FFA-NIC 
Sample Onset (˚C) Peak (˚C) 
CBZ 159.83, 190.81 166.59, 195.59 
NIC 129.62 135.08 
CBZ-NIC PM 126.10, 157.87 130.14, 161.86 
CBZ-NIC CO 159.33 160.31 





DSC curves patterns of CBZ III, NIC, CBZ-NIC co-crystals and a CBZ-NIC mixture are 
shown in Fig 19 and DSC data shown in Table 4.1.  NIC melted at 129.62°C and the 
CBZ-NIC co-crystals had a single melted point of 156.33°C suggesting the formation 
of a new, pure compound.  The CBZ-NIC mixture exhibited two major thermal events: 
the first endothermic-exothermic one being at 126.10°C due to the melting of NIC and 
the co-crystallisation of CBZ-NIC co-crystals, while the second endothermic peak, at 
157.87°C contributes to the melting of newly formed CBZ-NIC co-crystals under DSC 
heating. These results are identical to those reported [346]. 
 








The characteristic peaks of FFA I are at 2θ = 7.0°, 14.1°, 21.3° and 24.4° and 30.7°, 
all of which are identical to data reported by Guo [146]. TP’s characteristic diffraction 
peaks are at 2θ = 7.1°, 12.6° and 14.4°.  FFA-TP co-crystals show the characteristic 
diffraction peaks at 2θ = 5.9°, 10.0°, 11.2°, 15.6° and 26.7°, which agrees with previous 
reports. The physical mixtures showed the characteristic peaks of both FFA and TP at 
2θ = 7.1°, 12.6° and 14.1° respectively while the co-crystals show new peaks which 





are of a completely new material and are not the same as the individual components 








NIC’s characteristic diffraction peaks are at 2θ = 14.7°, 23.2° and 27.2°. FFA-NIC co-
crystals show the characteristic diffraction peaks at 2θ = 15.9°, 19.6°, 21.5°, 15.6° and 
23.6°, which agrees with previous reports [146]. The physical mixtures (not chemically 
bound) showed the characteristic peaks of both FFA and TP at 2θ = 14.6°, 17.6°, 19.5°, 
24.2° and 27.0° respectively while the co-crystals show new peaks which corresponds 
to the formation of a new crystal structure. The results agree with the DSC and FTIR 








Figure 26 - XRPD spectra of CBZ-NIC 
 
The characteristic diffraction peaks of CBZ III are at 2θ = 12.9°, 15.8°, 19.2° and 20.1°, 
all of which are identical to those of the reported data. NIC’s characteristic diffraction 
peaks are at 2θ = 14.7°, 23.2° and 27.2°. CBZ-NIC co-crystals show the characteristic 
diffraction peaks at 2θ = 6.5°, 8.7°, 9.9°, 13.1° and 20.2°, which agrees with previous 
reports [346]. The physical mixtures showed the characteristic peaks of both CBZ III 
and NIC while the co-crystals show new peaks which indicate that the co-crystals are 
of a completely new material and are not the same as the individual components or 
the physical mixture.  
 
4.4 Chapter Conclusion 
In this chapter, samples of FFA I, NIC, TP, CBZ, 1:1 FFA-NIC CO, 1:1 FFA-TP CO 
and 1:1 CBZ-NIC CO were characterized by ATR-FTIR, DSC and XRPD. All 
characterized results demonstrated that FFA-NIC CO, FFA-TP CO and CBZ-NIC CO 
were formed successfully. DSC analysis showed the co-crystals had distinct melting 
points compared to its individual components. FTIR spectrum shows the hydrogen 
bonding formation between FFA with NIC or TP and between CBZ and NIC during co-
crystals formation via –NH2 and –(C=O)- bonding. XRPD spectra exhibited new 
characteristic diffraction peaks existing in co-crystals compared with the pure FFA I, 
NIC and TP which indicates the resulting component was not a physical mixture, but a 





Chapter 5 – Investigating the effects 
of polymers on single crystals using 
experimental methods 
 
5.1 Chapter overview 
 
In this study, dissolution mechanisms of co-crystals in solution in the absence and 
presence of a pre-dissolved polymer was investigated. At the molecular level, we 
probed into how a co-crystal surface interacted with a polymer by investigating the 
etching pattern changes observed by using AFM, SEM and Raman spectroscopy in 
the presence/absence of polymers.  To reduce the effect of viscosity, a low polymer 
concentration of 0.2mg/mL was used. The big faces of FFA I, FFA-TP CO, FFA-NIC 
CO, CBZ III and CBZ-NIC CO single co-crystals were determined using X-ray 
diffraction and molecular scale models of their morphologies were created using 
Mercury 3.9 (The Cambridge crystallographic Data Centre, Cambridge, UK). These 
morphology models were also used to explain the properties of each face of a single 
co-crystal. AFM and SEM was used to detect precipitation of the parent drug onto the 
surface of the singe co-crystals and Raman spectroscopy was used to identify the 
precipitates. The surface roughness of the AFM measurements was calculated to give 
statistical data for comparison.  
 
5.2 Materials and Methods 
 
5.2.1 Materials  
 
FFA I, NIC, TP, CBZ III, FFA-TP CO, FFA-NIC CO, CBZ-NIC CO, PEG, PVP, PVP-
VA, ethyl acetate, acetonitrile and double distilled water were used in this chapter. 
Detailed information about these materials can be found in Chapter 3. 
 
5.2.2 Powder FFA and CBZ Co-crystals Preparation  
 
Co-crystals of FFA-NIC CO, FFA-TP CO and CBZ-NIC CO were used in this chapter, 





5.2.2 Experimental methods 
 
5.2.1.1 Dissolution experiments of single co-crystals 
 
Single co-crystals with well-defined and visually flat faces were carefully selected 
under a microscope for the etching dissolution studies. A single co-crystal was first 
mounted onto a cover glass using double-sided seal tape, in which the face of interest 
displayed at the top. The samples were then immersed in a beaker containing 20 mL 
of distilled water in the presence or absence of 0.2 mg/ml of PEG, PVP or PVP-VA. 
After a predetermined time interval shown in Table 5, the sample was taken from the 
solution and carefully patted using soft tissue papers to absorb the excess water. 
Finally, the sample was air-dried for at least 30 minutes before being studied by AFM, 
Raman spectroscopy and SEM. 
 













FFA-TP (0,0,1) 10 10 10 10 
FFA-NIC (0,-1,1) 7 7 7 7 
CBZ-NIC (0,0,1) 2 2 2 2 
 
 
5.2.1.2 AFM experiments  
 
The big faces of single co-crystals of FFA-TP, FFA-NIC, and CBZ-CIN before and after 
the etching dissolution tests were observed using an atomic force microscopy (AFM). 
The measurements were carried out using non-contact mode at room temperature 
using an AFM (Park XE100 by Park Systems) with high-aspect-ratio and tapping mode 
probe tips (Team Nanotech, Wetzlar, Germany). Three scans were taken on the same 
area at 10x10 µm2 for single co-crystals of FFA-TP and FFA-NIC and 5x5 µm2 for single 
co-crystals of CBZ-NIC. The resolution of measurement was 512×512 points with 
equal steps along the x and y directions. Based on the 2D etching patterns, 3D images 





Build5, Park Systems) and the surface roughness (Ra) was calculated using the 
equation below (Equation 19). Ra is calculated as an average of the surface roughness 
measured by calculating microscopic peaks and valleys. Peak to valley height is a 
measurement of the maximum peak height and the maximum depth of the surface 
irregularities over a given sample length. The largest peak or depth is then accepted 
for measurement as shown in figure 27. The value is obtained by measuring the area 
of the material above the arbitrarily chosen base line in the baseline in the section and 
the enveloping rectangle. 
 









where L is the evaluation length and Z(x) is the profile height function.  
 
 




5.2.1.3 Raman Spectroscopy  
 
The surfaces of the single co-crystals before and after the etching dissolution tests 
were studied by Raman spectroscopy. In order to determine the precipitation 
behaviour of the parent drugs of single co-crystals after dissolution in distilled water in 
the absence and presence of various polymers, an EnSpectr R532 Raman 





were placed in the sample holder and scanned at room temperature using 20-30mV 
output power laser source with a wavelength of 532 nm. The integration time was 
200ms, and each spectrum was obtained based on an average of 100 scans.  
 
5.2.1.4 Scanning Electron Microscope 
 
The surface topology of single co-crystals after the etching dissolution experiment was 
observed by scanning electron microscope (SEM) as the final step. In this study, SEM 
micrographs were photographed by a ZEISS EVO HD 15 scanning electron 
microscope (Carl Zeiss NTS Ltd., Cambridge, UK). The samples were first mounted 
with Agar Scientific G3347N carbon adhesive tab on Agar Scientific G301 0.5” 
aluminium specimen stub (Agar Scientific Ltd., Stansted, UK) and photographed at a 
voltage of 10.00 kV. The manual sputter coating S150B was used for gold sputtering 
of SEM samples. The thickness of gold coating was 15 nm. The results show the before 
and after dissolution images and indicates whether any parent drug has precipitated 





5.3.1 AFM results  
 
 Table 6 - AFM etching results of FFA-TP, FFA-NIC and CBZ-NIC co-crystal surfaces 
 
 FFA-TP FFA-NIC CBZ-NIC 
 Before After 3D and % increase Before  After 3D and % increase Before  After 




         
Ra (µm) 2.5 11.1 345 1.2 34.4 2862 0.9 10.7 1122 
PEG 
         
Ra (µm) 3.3 20.8 522 2.2 24.9 1037 3.5 25.7 643 
PVP 
      
  
 
Ra (µm) 3.4 7.2 115 1.9 7.6 300 1.0 4.0 316 
PVP-VA 
       
 
 
Ra (µm) 6.6 20.1 206 0.6 2.6 325 0.8 34.1 3960 
 
 
5.3.2 SEM experiments  
 
Table 7 - SEM etching results of FFA-TP, FFA-NIC and CBZ-NIC co-crystal surfaces 
 

































5.3.3 Raman experiments  
 




(a) FFA-TP surface 
 
   
(b) FFA-NIC surface 
 
     








The images created by the non-contact AFM of the faces of single co-crystals before 
and after the etching experiments were shown in Table 6. Prior to the etching 
experiments, the face (0-11) of FFA-NIC was relatively flat with its Ra valued from 0.6 
to 2.2 m. In comparison, the face (001) of FFA-TP and the face (011) of CBZ-NIC 
showed a high roughness from 2.5 to 6.6 m and from 0.8 to 3.5 m respectively. After 
etching in distilled water with or without PEG or PVP-VA, many small interpenetrating 
rectangle pits along with several long ditches formed on the face (001) of FFA-TP. On 
the other hand, circular pits appeared after etching with PVP. The roughness of the face 
(001) of FFA-TP increased after dissolution in all solutions, with a maximum increase 
of 522% in the presence of PEG and around 350% in distilled water. PVP caused a 
small increase of Ra, which was around 115%, and this was in contrast with the 
moderate increase caused by PVP-VA, which was about 206%.  
 
The face (0-11) of FFA-NIC, showed no pits after etching in distilled water or in the 
presence of PEG. However, the roughness of the face significantly increased to 2862% 
after etching in distilled water and to 1037% in the presence of PEG. Small pits 
appeared on the same face (0-11) after etching in the presence of PVP or PVP-VA, 
accompanied by a moderate increase of roughness to 300% in the presence of PVP 
and to 324% in the presence of PVP-VA.  
No pits were formed on the face (001) of CBZ-NIC after etching in distilled water with 
or without PEG, PVP or PVP-VA. A significant increase of the roughness was observed 
after etching in distilled water and in the presence of PVP-VA, 1122% in distilled water 
and 3960% in the presence of PVP-VA. A moderate increase of roughness, with a Ra 
of 643%, was seen for the same face (001) in the presence of PEG, and this was in 
contrast with that observed in the presence of PVP, which was 316%. AFM images and 
Ra values for the parent drug of FFA and CBZ can be found in Appendices A2. 
 
SEM was used to detect changes in the surface of the co-crystals and to validate the 
images revealed by the AFM. Raman spectroscopy was used to detect any altered 
chemical properties of the etched co-crystal surfaces (Fig. 27). No change was 
observed for FFA-TP, indicting no precipitation occurred during etching. This was in 
consistent with that observed with SEM (Table 7), in which no particle was found on the 





The characteristic peaks of FFA III were seen in Raman spectra after etching of FFA-
NIC single co-crystal in distilled water and in the presence of PEG. It showed double 
peaks, one at 370 cm-1 after dissolution of FFA-NIC in distilled water and one at 1170 
cm-1after dissolution in PEG, which was characteristic to FFA III. This indicates that FFA 
III might have crystallised on the surfaces of FFA-NIC surfaces during etching. This 
proposal was supported by the SEM images (Table 7), demonstrating the presence of 
rectangular shaped crystals on the dissolving surfaces of FFA-NIC. There was no 
change observed for the surfaces of FFA-NIC in the presence of PVP or PVP-VA (Table 
6). This seemed to be consistent with the results obtained by SEM (Table 7), which 
showed pits on the surface of the co-crystal. These results indicated that the 
recrystallization of the parent drug, FFA, might have been inhibited during co-crystal 
dissolution due to the effect of PVP or PVP-VA.  
 
The particles that had recrystallised were clearly shown on the surfaces of CBZ-NIC 
(Table 7) after etching with or without PEG, PVP or PVP-VA. While the Raman spectra 
of the same surfaces (Fig. 27) showed that, in the absence or presence of PEG, the 
surfaces of CBZ-NIC were the same as those of CBZ dihydrate, from which the 
characteristic double peaks of 1030 cm-1 and triple peaks between 780 cm-1 to 820 cm-
were shown. This suggested that the CBZ dihydrate could have recrystallised and 
completely covered the surfaces of CBZ-NIC. In the presence of PVP or PVP-VA, the 
Raman spectra of the surfaces of CBZ-NIC surfaces displayed as combined spectra of 
CBZ-NIC and CBZ dihydrate (Fig.27), indicating that PVP or PVP-VA during the 
dissolution of the co-crystal should be able to partially prevent the recrystallization of 
CBZ dihydrate. The SEM images for the parent drugs FFA and CBZ can be found in 
Appendices A3. 
 
The etching experiments carried out in this research exhibited FFA-NIC and CBZ-NIC 
as surface precipitation co-crystals, and FFA-TP as bulk precipitation co-crystals. Both 
PVP and PVP-VA proved to be good surface precipitation inhibitors for FFA-NIC, and 
demonstrated they could completely inhibit the recrystallization of FFA III on the surface 
of FFA-NIC. In contrast, PVP and PVP-VA could only partially inhibit the recrystallization 
of CBZ dihydrate on the surface of CBZ-NIC while PEG was not considered as surface 
crystallization inhibitor for FFA-NIC and CBZ-NIC. The presence of PVP or PVP-VA 
decreased the dissolution rate of FFA-TP, lowering the solubility and dissolution of the 
co-crystals. Therefore, for bulk precipitation co-crystals, an addition of a solubilizer, 





5.5 Chapter conclusion 
 
In this chapter, the effects of PEG, PVP and PVP-VA was investigated as surface 
precipitation inhibitors. AFM and SEM were used to look at etching patterns on the 
surfaces of co-crystals before and after dissolution in distilled water in presence of 
with/without PEG, PVP or PVP-VA. Raman spectroscopy was used to identify the 
chemical change on the surface of co-crystals which would indicate recrystallisation of 
parent drug. FFA-NIC and CBZ-NIC showed recrystallisation on the surface – identified 
using Raman spectroscopy - as the parent drug of FFA III and CBZ dihydrate had 
recrystallized on the surface of FFA-NIC and CBZ-NIC respectively. FFA-NIC and CBZ-
NIC exhibited surface precipitation while FFA-TP showed no precipitation on the 
surface but could have precipitated in the bulk solution. Both PVP and PVP-VA proved 
to be good surface precipitation inhibitors for FFA-NIC and could only partially inhibit 




















Chapter 6 - Investigating the influence 
of polymers on co-crystal dissolution 
using Molecular Modelling Techniques 
 
6.1 Chapter overview  
 
In this chapter, the influence of polymers PEG, PVP and PVP-VA on co-crystal 
dissolution surfaces was investigated using molecular modelling techniques. The 
morphology of single co-crystals and XRPD patterns were predicted and compared to 
the experimental shapes and XRPD patterns. Polymers of PEG, PVP and PVP-VA were 
built using a polymer builder and were energy minimised using anneal dynamics. The 
polymer-co-crystal surface system was built and molecular dynamic simulations were 
run. The molecular interactions – hydrogen bonding, electrostatic attractions and van 
der Waals – were calculated as well as the mean square displacement.  
 
6.2 Molecular modelling methods 
 
6.2.1 Single co-crystal morphology prediction and face indexing 
 
To detect the exposed co-crystal faces to the dissolution media during AFM 
measurements, the morphologies of the co-crystals were produced using Mercury CSD 
4.1.2 (The Cambridge crystallographic Data Centre, Cambridge, UK). Using Conquest 
2.0.1 (reference codes: ZIQDUA for FFA-TP, EXAQAW for FFA-NIC, and UNEZES for 
CBZ-NIC) from the Cambridge Structural Database (CSD), the unit cells of single co-
crystals were obtained. The morphology of a single co-crystal was predicted using the 
Bravais-Friedel-Donnay-Harker (BFDH) crystal morphology tool. The predicted 
morphologies were then validated through comparing the predicted XRD patterns using 
Powder diffraction in the Reflex module (BIOVIA Material studio 2017 R2) with 
experimental measurements. The index of a crystal face was determined by comparing 







6.2.1 Building of polymer using polymer builder 
 
Polymers of PEG, PVP and PVPVA were built using the polymer builder in Material 
studio. It would have been ideal to build a whole polymer chain of each polymer used 
in the simulations, as the number of monomers would affect its properties and the 
interactions of polymer molecules with the crystal surface. However, to save 
computational time and resources and to generate comparable results with 
experiments, the polymers of PEG and PVP built represented 20% of the real polymer 
weights, i.e., the numbers of monomer units were given as 18 for PEG and 72 for PVP.  
The chemical structure of a monomer of PEG or PVP was illustrated, from which the 
head and tail atoms were specified to expand the required chain length of the polymer 
at a torsion angle of 180°. For PVP-VA however, it was a bit complicated and had to be 
made smaller (Table 8).  The number of monomers of PVP used was 303 and the 
number of VA was 202 in the etching experiments shown in Table 9. To confine PVP-
VA in the simulation box, the number of monomers had to be decreased to 10% of its 
real polymer weight, i.e., 31 for PVP monomers and 21 for VA monomers. The 
monomers of PVP and VA were drawn individually and were then connected randomly 
as a copolymer of PVP-VA using the polymer builder. 
For the conformational structure of a polymer, in order to find the global minimum of 
potential energy, anneal dynamics was performed by periodically increasing and then 
decreasing the temperature from 100 to 1000K over 10 annealing cycles. Anneal 
dynamics was performed at NVT (constant number of particles, constant volume, and 
constant temperature) ensemble at the time step of 1fs. The lowest energy of the 
polymer configuration was selected for MD simulation.  The illustration of the procedure 
is shown in Fig. 29. The final structure of each of the polymers with minimised energy 










































Molar weight of 
material used in 
the experiments 










6.2.2 Building of crystal surface 
 
The unit cells of co-crystals of FFA-TP, FFA-NIC, and CBZ-NIC which was taken from 
CSD were imported to material studio. Steepest descent algorithm in Forcite module 
for energy minimization was used to optimise the geometries of the unit cells. Details of 
each unit cell after the geometry optimisation as well as the size of the simulation boxes 
can be found in the table below (Table 10). The surfaces of each individual crystals with 
a depth of two unit-cells was then generated by cleaving the required face 
corresponding to the AFM measurements. For the polymers to be contained, the crystal 
surfaces were extended at U and V directions at different magnitudes shown in Table 
10. Above the crystal surface, a thick vacuum slab of 100Å was built for each of crystals 
studied which forms the simulation box. 
 





Number of Unit cells for 
crystal layer 
Dimensions of the simulation 
box (Ǻ) 
  U V thickness a b c 
FFA-
TP 
(0,0,1) 12 11 2 83.9172 111.397 136.017 
FFA-
NIC 
(0,-1,1) 18 4 2 91.8972 109.106 129.989 
CBZ-
NIC 
(0,0,1) 18 5 2 91.7298 131.870 126.690 
 
 
6.2.3 Building polymer and crystal surface together 
 
Prior to a MD simulation, each of the polymers was placed approximately 5Å away from 
the centre of a crystal surface.  The initial position of a polymer on the crystal surface 
could vary slightly, but it was found that the simulation results were not affected. The 
polymer-crystal system was first subjected to geometry optimisation by using the 
steepest descent algorithm until the energy had reached a minimum. The crystal 
surface was fixed before starting a MD simulation and therefore only the polymer was 
movable during the time of simulation. MD simulations were performed using periodic 





off for non-bonded interactions of van der Waals and electrostatic were 12.5Å and for 
Hydrogen bonds it was 4.5Å. Simulations were run for 150ps at a time step of 1fs until 
equilibrium had reached evidenced by a plateau on the energy vs time graph 
(Appendices A4 Table 1). Nosé–Hoover thermostat algorithm was used to control the 
temperature. MD simulations were then proceeded for a further 50ps at the same 
settings for data analysis. Data was saved every 5ps for each of the MD simulations. 
Forcite analysis tools was used to analyse the MD results, including mean square 
displacement (MSD) and binding energy between the polymer and crystal surface.  
 
 
































6.3.1 Morphology prediction and face indices of co-crystals 
 
The morphologies of the co-crystals were predicted using Mercury CSD 4.1.2 (Table 
11), which was consistent with the observed images of the co-crystals. Comparison of 
the predicted XRD patterns with the experimental XRPD results (Table 11) confirmed 
the structures of the predicted co-crystals, verifying all the key characteristic peaks of 
the co-crystal allowing to be predicted accurately. The predicted morphology of FFA-
TP showed dominant big faces of (001) and (00-1), large side faces of (0-10) and (010) 
and smaller side faces of (100) and (-100). The dominant face of (001) exposes 
trifluromethylbenzene from the FFA at a perpendicular angle. This suggested that the 
reactive functional groups had the least exposure on the dominant faces, whereas the 
side faces were more reactive due to the existence of more hydrogen-bond donors and 
acceptors. The predicted morphology of FFA-NIC showed the dominant faces of (0-11) 
and (01-1), the smaller faces of (011) and (0-1-1) and the smallest faces of (-100) and 
(100). The functional group exposed on the dominant face (0-1-1) were carbon, fluorine 
and hydrogen atoms. The morphology of CBZ-NIC displayed the dominant faces of 
(011) and (0-1-1), and the smaller faces of (01-1) and (0-11), where the face (011) 




































































6.3.2 Using MD simulation to identify the effect of polymers on co-crystal 
dissolution 
 
Molecular dynamic simulations were conducted to determine the dynamic behaviour 
change of polymers on the surfaces of co-crystals. A simple system was chosen by not 
including any solvent molecules in the work. This was differed from the real system; the 
simulated results only aimed to serve as qualitative indictors of the inhibitory effects of 
polymers on the precipitation of the parent drug during dissolution. Nonetheless, the 
MD simulation allowed the visualization of the kinetic effects of polymers on the 
surfaces of co-crystals. Tables 12-14 shows the polymers approaching the surfaces of 
FFA-TP, FFA-NIC and CBZ-NIC and a summary of the polymer stabilisation time is 
presented in Table 15. The final polymer conformations on the surfaces of the co-
crystals and the interaction energies are presented in Table 16 and Table 17 
respectively.  
 
Table 13 shows the mechanism of PEG, PVP and PVP-VA as it approaches and 
adsorbs on the surface (0-11) of FFA-NIC. PEG reached equilibrium within 30ps on the 
surface of FFA-NIC. There was a stable adsorption of PEG on the crystal surface. Both 
PVP and PVP-VA were able to move towards and interact with the surface of FFA-NIC 
after 10 ps. PVP started to adsorb on the surface after 60ps, and the whole PVP coiled 
and distributed evenly. Whereas some fragments of PVP-VA chain seemed to be quite 
far away from the surface, the PVP-VA chain distributed evenly on the co-crystal 
surface after 150 ps. These indicates that PVP-VA have the lowest adsorbing rate on 
the surface when compared to the other polymers. When comparing the face (001) of 
FFA-TP and CBZ-NIC, PEG had the fastest adsorbing rate and PVP-VA had the lowest 
one. The snapshots taken at different simulation times were shown in Table 12 and 
Table 14, respectively. 
 
The conformation of polymers on the surfaces of co-crystals at the equilibrium point of 
200ps is shown in table 16. The intermolecular interaction energies between the 
polymers and the surfaces of co-crystals surfaces were calculated at the same time 
(Table 17). All of the calculations showed negative values, implying that the adsorption 
process of the polymers on the surfaces of co-crystals were exothermic. Among the 
chosen polymers, PEG had the lowest binding, electrostatic and van der Waals 
energies and laid flat and straight against the surfaces of the co-crystals (table 16). PEG 
could only form hydrogen bonding with the surface (001) of FFA-TP, due the arisen O 





extremely low. Neither the face (0-11) of FFA-NIC nor the face (011) of CBZ-NIC formed 
hydrogen bonds with PEG, due to the lack of hydrogen bond donor or receptor on the 
surfaces of the co-crystals (Table 11). The binding and van der Waals energies for PVP 
and PVP-VA were comparable (Table 17), and no hydrogen bonding was observed 
between PVP or PVP-VA on the surfaces of the co-crystals. 
 
The negative electrostatic energy for PVP was strong whereas the van der Waals 
interaction was weak. As shown from the conformations at equilibrium (table 16), PVP 
did not spread out on the surfaces of the co-crystals. Instead, it coiled up, particularly 
for the surface (0-11) of FFA-NIC. The van der Waals energies and electrostatic 
attractions between PVP-VA and the surfaces of the co-crystals were similar. And PVP-
VA was able to spread out and bind to the surfaces of the co-crystals (table 16). 
Table 18 shows the mean squared displacement and demonstrates the mobility of the 
polymers on the surfaces of the co-crystals. It seemed that PVP-VA had the highest 
mobility for the surface (001) of FFA-TP and the surface (0-11) of FFA-NIC. PVP had a 
slightly higher mobility than PEG for the surface (0-11) of FFA-NIC. No significant 
difference was observed for the mobility of PEG, PVP or PVP-VA for the surface (011) 
of CBZ-NIC. 
 
Table 12 - Snapshots of polymers on FFA-TP surfaces at 298k at 0, 10, 30, 60, 100 
and 150ps 
Time (ps) FFA-TP 
 PEG PVP PVP-VA 
0 






   
30 
   
60 
   
100 
   







Table 13 - Snapshots of polymers on FFA-NIC surfaces at 298k at 0, 10, 30, 60, 100 
and 150ps 
Time (ps) FFA-NIC (0-11) surface 








   
150 










   
150 















Table 14 - Snapshots of polymers on CBZ-NIC surfaces at 298k at 0, 10, 30, 60, 100 
and 150ps 
 
Time (ps) CBZ-NIC (011) surface 
 PEG PVP PVP-VA 
0 
   
10 
   
30 
   
60 
   
100 






   
 
 




Table 16 - Conformation of polymers on co-crystal surfaces at equilibrium at 298K and 
200ps 
 
Stabilisation time (ps) 
 
 FFA-TP FFA-NIC CBZ-NIC 
PEG 30 30 10 
PVP 100 60 100 
PVPVA 150 150 150 




















Table 17 - Binding energy, hydrogen bonding, van der Waals and electrostatic 
attractions on co-crystal surfaces 
 










PEG -44.415 -0.016 14.55 -12.17 
PVP -149.05 0 351.075 -1734.36 
PVP-VA -90.48 0 318.27 -490.02 
FFA-NIC 
PEG -54.823 0 7.948 -10.271 
PVP -161.68 0 360.30 -1740.83 
PVP-VA -122.90 0 255.91 -490.84 
CBZ-NIC 
PEG -45.151 0 16.185 -13.816 
PVP -208.835 0 350.682 -1729.835 



































The interactions of the polymers on the surfaces of the co-crystals played an essential 
role in controlling the dissolution and morphological changes of the co-crystals during 
the dissolution process. The MD simulations as well as the etching experiments indicate 
that, when compared to PVP or PVP-VA, very low interaction energy existed between 
PEG and the surfaces of the co-crystals. PEG therefore, was not an effective inhibitor. 
In contrast to PVP-VA, PVP had greater interaction energies (Table 17). It is worth 
noting that the calculated interaction energy for PVP was based on 20% of its actual 
polymer weight, and PVP-VA was based on 10% of its actual polymer weight. 
Therefore, it was predicted theoretically that PVPVA had stronger interaction with the 
surfaces of FFA-NIC or CBZ-NIC in comparison to PVP. 
 
Interestingly, the above theory could not be applied to the observations derived from 
the etching experiments which demonstrates that PVP was more effective in inhibiting 
parent drug precipitation in comparison to PVP-VA. This observation was consistent 
with previous dissolution performance parameter (DPP) investigations for FFA-NIC, 
demonstrating a 64% increase of AUC (area under curve) in the presence of PVP 
whereas a 60% increase in the presence of PVP-VA [140]. The results indicated that 
other factors, such as non-covalent bonds existed between the polymers and the 
surfaces of co-crystals or the polymer mobility and conformation, might play an 
important role in modulating the co-crystal dissolution and parent drug precipitation. 
The etching experiments in chapter 5 and the simulations carried out for this research 
looked at the biggest and most stable faces of the co-crystals, which were from the 
hydrophilic regions of the molecules. The studies showed that PVP had weak van der 
Waals interaction and greater electrostatic energy (Table 17), which contributes to its 
low mobility on the surfaces of co-crystals (Table 18). PVP adsorption on the surfaces 
of co-crystals led to the formation of a steric hindrance layer, which prevented solvent 
molecules from contacting the co-crystal surface particles and subsequently reducing 
the dissolution rate. Furthermore, the layer prevented the parent drug supersaturation 
around the dissolution surface and inhibited the precipitation of the parent drug.  
Additionally, a conformational change was observed for PVP when it displayed the 
inhibitory effect by coiling up when they adsorbed on the surfaces of the co-crystals. 
This contrasted with PVP-VA, which became more mobile on the surfaces of the co-
crystals (Table 18), making it difficult to form a stable steric hindrance layer. Therefore, 





6.5 Chapter Conclusion 
 
This research provided insights into the mechanisms of co-crystal dissolution and 
described inhibitory functions of polymers for precipitation, which is of great value to the 
development of novel co-crystal based formulations. It was highly promising that such 
approaches would be set up as an essential tool during the routine process of 
manufacturing pharmaceutical co-crystals. The results showed that PEG was not an 
effective inhibitor while PVP and PVP-VA was effective. In contrast to PVP-VA, PVP 
had greater interaction energies and was more effective in inhibiting parent drug 
precipitation in comparison to PVP-VA 
It is also worth noting that the MD simulations without considering the dissolution 
medium may be too simplistic as a tool for the selection of polymeric excipients in the 
formulation because nucleation and growth of the parent drug could take place in the 
diffusion layer. Therefore, a full MD simulation will be required to provide a 


















Chapter 7 - Influence of polymers on the 
diffusion coefficient of drug molecules 
using NMR techniques 
 
7.1 Chapter overview 
 
To gain understanding into the mechanism of the supersaturated solution in the 
presence of polymers, the atomic-level of molecular interactions among the parent drug, 
co-formers and polymers were studied using one-dimensional proton nuclear magnetic 
resonance (1H NMR) spectroscopy and DOSY spectroscopy. Solution 1H NMR is a 
powerful tool for investigating and understanding the molecular level of drugs, in order 
to examine interactions such as hydrogen bonding and aggregation properties. The 
chemical shifts in 1H NMR spectra indicates differences in the chemical environment of 
molecules and widths of the reflect molecular mobility [140]. 1H NMR studies were 
conducted in singular, binary and ternary components in solutions containing parent 
drugs of FFA or CBZ, co-former and polymer to determine the possibility of interactions 
of drug/co-former, drug/polymer and co-former/polymer in low polarity solvent 
deuterated chloroform (CDCl3). DOSY spectroscopy was used to calculate the diffusion 
coefficient of the drugs, co-formers and polymers in CDCl3. 
 
7.2 Materials and methods 
 
FFA I, NIC, TP, CBZ III, PEG, PVP, PVP-VA, acetonitrile, ethyl acetate, CDCl3 and 
double distilled water were used in this study. Detailed information of these materials 
can be found in Chapter 3. 
 
7.2.1 Powder FFA and CBZ Co-crystals Preparation  
 
Co-crystals of FFA-NIC CO, FFA-TP CO and CBZ-NIC CO were used in this chapter, 







7.2.2 NMR and DOSY Measurements 
 
JEOL ECZ 600R series FT-NMR Spectrometer was used to identify the interactions 
occurring between the drug, co-former and polymer in deuterated chloroform solution. 
Tetramethylsilane (TMS) spectra was used as the internal standard. 
1H NMR and DOSY experiments were used to probe interactions among drug, co-
former and polymer in solution. The spectra of Singular components (FFA, TP, NIC, 
CBZ, PEG, PVP,PVP-VA) the binary components (FFA-TP, FFA-NIC, CBZ-NIC, FFA-
PEG, FFA-PVP, FFA-PVP-VA, CBZ-PEG, CBZ-PVP, CBZ-PVP-VA, NIC-PEG, NIC-
PVP, NIC-PVP-VA, TP-PEG, TP-PVP, TP-PVP-VA) and the ternary components (FFA-
TP-PEG, FFA-TP-PVP, FFA-TP-PVP-VA, FFA-NIC-PEG, FFA-NIC-PVP, FFA-NIC-
PVP-VA, CBZ-NIC-PEG, CBZ-NIC-PVP, CBZ-NIC-PVP-VA) were analysed for any 
interactions between the components. 2 different concentrations of parent drug were 
prepared including 2.4mg/ml and 2mg/ml. 2.4mg/ml drug concentration was studied in 
the presence of 0.3mg/ml PEG, PVP or PVP-VA and 2mg/ml drug concentration was 
studied in the presence of 0.5mg/ml and 1mg/ml PEG, PVP or PVP-VA. In order to 
investigate the effect of self-dissociation of the drug, it was necessary to study a slightly 
higher concentration of the drug (2.4mg/ml) at low polymer concentrations (0.3mg/ml). 
To mimic a co-crystal system, an equal molar concentration of a co-former as that of 
FFA or CBZ was prepared in solution. NMR techniques was used to calculate the proton 
shift and diffusion coefficient of API and co-former molecules in singular, binary, and 
ternary systems. 1H proton spectra were achieved after 64 scans, with a relaxation 
delay of 7s at a controlled temperature of 25°C. For DOSY, stimulated spin echo with 
bipolar gradient pulses was employed for self-diffusion coefficient measurement. DOSY 
spectra were achieved after 32 scans, with a relaxation delay of 6s, at a controlled 














1H NMR experiments were carried out to investigate the interactions among FFA, CBZ, 
co-formers and polymers in solution. This research focused on examining the 
characteristic chemical shifts of the protons in each of the molecules of FFA, TP, CBZ 
and NIC affected by their hydrogen bonding interactions and self-aggregation 
properties in solution in the presence or absence of a polymer of PEG, PVP or PVP-
VA. Drug structures with the proton identification and with the respective peak positions 
are presented in Table 19 and Table 20. 
 
Investigations were carried out for: 
i) the chemical shifts of the singlet peak of Hj and two doublet peaks of Hi of FFA;  
ii) the chemical shifts of Ha, Hb and Hc of NIC; 
iii) the chemical shifts of Ha, Hb, Hc and Hd of TP; 
iv) the chemical shifts of Ha and Hb of CBZ. 
The proton details of each molecule can be found in the table below (Table 19).  
 



























































7.3.1 1H NMR Analysis of Binary Components  
 
The results below show the 1H NMR analysis of singular and binary components of 2 
different concentrations of parent drug including 2.4mg/ml and 2mg/ml of FFA and CBZ 
with 0.3mg/ml, 0.5mg/ml and 1mg/ml PEG, PVP or PVP-VA. The proton graphs were 
analysed using Mnova 14.2.0 by Mestrelab. The full NMR spectra can be found under 











7.3.1.1 In presence of 0.3mg/ml PEG, PVP or PVP-VA  
 
Table 21 - Singular and binary component NMR analysis of FFA, TP and NIC with 
















Proton Hj Proton Hh 
Proton Hb Proton Hc and Hd 






Table 22 - Singular and binary component NMR analysis of CBZ and NIC with 






















Proton Ha and Hb Proton Hc 





7.3.1.2 In presence of 0.5mg/ml PEG/PVP/PVP-VA 
 
Table 23 - Singular and binary component NMR analysis of FFA, TP and NIC with 
















Proton Hj Proton Hh 
Proton Hc and Hd Proton Hb 






Table 24 - Singular and binary component NMR analysis of CBZ and NIC with 
0.5mg/ml PEG, PVP or PVP-VA 
  
 
7.3.1.3 In presence of 1mg/ml PEG, PVP or PVP-VA 
 
Table 25 - Singular and binary component NMR analysis of FFA, TP and NIC with 



















Proton Hj Proton Hh 
Proton Ha and Hb Proton Hc 













Table 26 - Singular and binary component NMR analysis of CBZ and NIC with 1mg/ml 









Proton Hc and Hd Proton Hb 
Proton Ha and Hb Proton Hc 









































Difference of peak shift 
- - 




0.3mg/ml 0.3mg/ml 0.5mg/ml 1mg/ml 0.5mg/ml 1mg/ml 0.5mg/ml 1mg/ml 
2mg/ml FFA 
9.425 0.005 0.017 0.007 0.006 0.009 0.031 0.058 0.025 0.037 
8.047 0 -0.003 -0.002 -0.001 -0.002 -0.004 -0.009 -0.003 -0.005 
1.28mg/ml TP 
7.809 0 -0.002 0.001 0.006 0.01 0.004 0.004 0.006 0.007 
3.646 -0.003 -0.004 -0.003 0.002 0.003 0.002 0.002 0.002 0.002 
3.468 -0.004 -0.006 -0.004 0.003 0.005 0.003 0.002 0.003 0.004 
0.86mg/ml NIC 
9.006 0.001 0.001 0.001 0.001 0.002 0.002 0.003 0.002 0.002 











In this study FFA and CBZ cocrystals were analysed in the presence of three different 
concentrations of polymers – 0.3mg/ml, 0.5mg/ml and 1mg/ml of PEG, PVP or PVP-
VA. Table 21 and 22 show the chemical shifts of the characteristic peaks of FFA-TP, 
NIC and CBZ in 0.3mg/ml PEG, PVP or PVP-VA. Peak shift details can be found in the 
Appendices under A5 Table 6.   
At low polymer concentration, for all three polymers, the chemical shift of Hj of FFA 
showed downfield shift - Δδ = 0.005 with PEG, Δδ = 0.017 with PVP and δΔ = 0.007 
with PVP-VA - indicates hydrogen bond interaction between the O-H of the carboxylic 
acid functional group of FFA with the carbonyl O functional group of PEG, PVP or PVP-
VA. The chemical shift of Hh of FFA showed an up-field shift in the presence of PVP 
and PVPVA – Δδ = -0.003 and Δδ = -0.002 respectively which indicates a different type 
of interaction is taking place. Although the functional group, O=C of the carboxylic acid 
on the FFA is not involved with the interaction with the polymers, the long backbone 
chains of polymers can disturb the intramolecular interaction of N-Hj∙∙∙O=C and 
subsequently affect the confirmation of the FFA. In the presence of 0.5mg/mL polymer 
concentration (Table 23), the effect of both down-fielding and up-fielding was increased 
for FFA, with the highest increase being in the presence of PVP as the Hj showed a 
downfield shift of – Δδ = 0.031. PEG showed a slight increase (– Δδ = 0.006) and PVP-
VA showed a moderate increase (– Δδ = 0.025). The chemical shift of Hh showed an 
upfield shift of – Δδ = -0.001 for PEG, – Δδ = -0.004 for PVP and – Δδ = -0.003 for PVP-
VA. In the presence of 1mg/ml polymer (Table 25), there was a further increase in the 
down-fielding and up-fielding effect. Hj proton showed a chemical shift of – Δδ = 0.009 
for PEG, – Δδ = 0.058 for PVP and – Δδ = 0.037 for PVP-VA while the chemical shift 
for Hh did not change. In all three polymer concentrations, PVP had the highest 
hydrogen bond interactions between the O-H of FFA and the carbonyl O of PVP, 
followed by a moderate interaction of PVP-VA and low interaction of PEG. Furthermore, 
in comparison to PVP-VA, PVP showed a slightly broader peak, demonstrating that 
PVP can significantly suppress the mobility of FFA molecules in solution. 
1H NMR spectra of TP samples are complex, as they can be affected by solute-solvent, 
solute-solute and solute-polymer interactions [178]. In CDCl3, dimerization of TP 
molecules is found to be the controlling factor affecting the 1H chemical shifts of TP 
[347]. Due to TPs being good proton donors, PVP-VA can disrupt TP dimers in solution, 
indicating shifts of proton of TP at a low polymer concentration of 0.3mg/mL as shown 
in Table 21. The chemical shift of Hb, in the presence of PEG showed no change while 
the Hc and Hd proton showed an up-field shift of Δδ = -0.003 and Δδ = -0.004 





an up-field shift for Hb proton and a downfield shift for Hc and Hd proton. In all three 
concentrations, a peak change was seen for the Hb proton, where the double peak had 
changed to a narrow single peak.   
The chemical shifts of NIC (corresponding to the FFA ratio) shows a slight downfield 
shift of Δδ = 0.001 for the Hc proton in the presence of all three polymers. Ha protons 
show an up-field shift in the presence of the polymers with Δδ = -0.011 in the presence 
of PEG and PVP and Δδ = -0.066 in the presence of PVP-VA (Table 21). In of 0.5mg/ml 
polymer, the chemical shift of Hc proton showed an increase in the down-fielding effect 
in presence of PVP and PVP-VA ( Δδ = 0.002) while Ha protons showed a chemical 
shift of Δδ = 0.013 for all three polymers as seen in Table 23. 1mg of polymer further 
increased the Ha protons in the presence of PEG (Δδ = 0.002) and PVP (Δδ = 0.003) 
while PVP-VA remained the same (Table 25). The chemical shift of Hc protons had an 
increase in the up-fielding shift where the change was Δδ = -0.031 for all three polymers. 
Due to no significant change for the chemical shift of Ha protons, it can be implied that 
the changes are due to hydrophobic or hydrophilic environments in the presence of 
polymers rather than due to any hydrogen bonding. On the other hand, hydrogen 
bonding is present between the Hc proton and the carbonyl O functional group of 
0.3mg/ml PVP-VA and 1mg/ml PEG, PVP and PVP-VA.     
The chemical shifts of NIC (corresponding to the CBZ ratio) showed similar changes as 
the NIC corresponding to FFA. However, in the presence of 0.3mg/ml a down-fielding 
chemical shift of Δδ = 0.035 was seen for the Hc proton. It is worth noting that the 
concentration of the drug in the presence of 0.3mg/ml polymer is slightly higher 
(2.4mg/ml) in comparison to the drug concentration in the other two polymers. This high 
drug concentration – low PEG polymer concentration could have resulted in hydrogen 
bond formation.  
The chemical shift of the Hb in CBZ showed no change in the presence of PEG and an 
up-field shift of δΔ=-0.001 for both PVP and PVP-VA which indicates a hydrogen bond 
interaction between the N-H of the CBZ and the carbonyl O functional group of the 
polymers. In contrast, the chemical shift of Ha showed a downfield shift of Δδ = 0.002 
for both PVP and PVP-VA. No change was found in the presence of PEG. In the 
presence of 0.5mg/ml polymer (Table 24), the up-fielding shift of Ha in CBZ only showed 
a slight increase of δΔ = -0.001 for PEG, δΔ = -0.002 for PVP and -0.002 for PVP-VA. 
The chemical shift of Hb showed no change. Increasing the polymer concentration to 
1mg/ml (Table 26) showed slight difference in the chemical shift for Ha proton in 





PVP-VA increased slightly downfield to δΔ = -0.001. On the other hand, the chemical 
shift of Hb in CBZ, showed a moderate increase in the down-field effect in the presence 
of PEG (δΔ = 0.003), PVP (0.006) and PVP-VA (δΔ =0.004). NMR data strongly 
suggests CBZ does not interact much in the presence of polymers which indicates that 
the chemical environment of CBZ in each solution was not significantly different. CBZ 
in the presence of PVP showed a slightly broader peak for the Ha proton which 
attributed to the changes in molecular mobility where the suppression of the molecular 
mobility is occurring. The chemical shift of the Ha proton in CBZ drug peak can be 
attributed to the differences in the chemical environment surrounding the drug, for 
example, hydrophobic or hydrophilic environments in the presence of polymers, rather 
than any hydrogen bond interactions [348].  
 
7.3.2 1H NMR Analysis of Ternary Components 
 
The results below show the 1H NMR analysis of the binary and ternary components of 
co-crystals with 2 different concentrations of parent drug including 2.4mg/ml and 
2mg/ml of 1:1 FFA-TP, 1:1 FFA-NIC and 1:1 CBZ-NIC with 0.3mg/ml, 0.5mg/ml and 
1mg/ml PEG, PVP or PVP-VA. The full NMR spectra of the components can be found 
under A5 Table 1-4 in appendices.  
 
7.3.2.1 In presence of 0.3mg/ml PEG/PVP/PVP-VA 
 
Table 28 - Binary and ternary component NMR analysis of 1:1 FFA-TP and FFA-NIC 





















   
NIC 









Proton Hj Proton Hh 
Proton Hc and Hd Proton Hb 





Table 29 - Binary and ternary component NMR analysis of 1:1 CBZ-NIC with 














7.3.2.2 In presence of 0.5mg/ml PEG, PVP or PVP-VA 
 
Table 30 - Binary and ternary component NMR analysis of 1:1 FFA-TP and 1:1 FFA-










Proton Hj Proton Hh 
Proton Ha and Hb Proton Hc 























Proton Hj Proton Hh 
Proton Hc and Hd Proton Hb 





Table 31 - Binary and ternary component NMR analysis of CBZ-NIC with 0.5mg/ml 














7.3.2.3 In presence of 1mg/ml PEG/PVP/PVP-VA 
 
Table 32 - Binary and ternary component NMR analysis of 1:1 FFA-TP and 1:1 FFA-










Proton Hj Proton Hh 
Proton Ha and Hb Proton Hc 

























Proton Hj Proton Hh 
Proton Hc and Hd Proton Hb 





Table 33 - Binary and ternary component NMR analysis of 1:1 CBZ-NIC with 1mg/ml 

























Proton Ha and Hb Proton Hc 










Difference of peak shift 
- - 












9.423 0.004 0.015 0.004 0.006 0.011 0.025 0.048 0.025 0.032 
8.071 -0.001 -0.003 -0.001 -0.001 -0.002 -0.006 -0.009 -0.005 -0.005 
TP 
7.841 0 -0.002 -0.001 -0.001 -0.001 -0.002 -0.005 -0.001 -0.007 
3.657 -0.001 -0.002 -0.001 -0.001 -0.002 -0.001 -0.003 -0.001 -0.002 
3.482 -0.001 -0.002 -0.001 -0.002 -0.002 -0.003 -0.004 -0.002 -0.002 
FFA-NIC 
FFA 
9.551 0.002 0.003 0.003 0.007 0.012 0.02 0.022 0.018 0.022 
8.067 -0.001 -0.002 0 -0.001 -0.008 -0.003 -0.014 -0.004 -0.011 
NIC 
9.038 0 -0.003 0.001 0.001 0 0 -0.001 0.001 0 
6.161 0.003 -0.032 0.005 0.008 -0.01 0.003 -0.01 0.006 -0.018 
2mg/ml CBZ 
6.935 0 -0.001 -0.001 0 -0.001 -0.001 -0.002 -0.001 -0.001 
4.394 0 0.002 0.002 0 0.003 0 0.006 0 0.004 
1.03mg/ml NIC 
9.007 0.002 0.001 0 0.001 0.001 0.002 0.003 0.002 0.002 
5.742 0.035 0.007 0.007 0.008 0.015 0.013 0.015 0.013 0.015 
CBZ-NIC 
CBZ 
6.932 0 0 0.001 0.001 -0.001 -0.001 -0.002 -0.001 -0.002 
4.452 0 0.001 -0.016 0 0.001 0.04 0.004 0.039 0.008 
NIC 
9.002 0.001 0.001 0.002 0.001 0.005 0.001 0.006 0.002 0.004 





Ternary components consisted of the mixtures of FFA and CBZ at a concentration of 
2mg/mL or 2.4mg/ml with its equal molar concentration of a co-former of NIC or TP in 
different concentrations of a polymer in CDCl3 presented in Tables 28-33. The 
concentrations of the polymers remained at 0.3mg/ml, 0.5mg/ml or 1mg/ml of PEG, 
PVP or PVP-VA.  
Regarding mixture of FFA and TP in CDCl3, in the presence of 0.3mg/ml PEG, the Hj 
proton of FFA had a downfield shift of Δδ = 0.004, PVA showed a shift of Δδ = 0.015 
and PVP-VA, Δδ = 0.004. The Hh protons showed an up-field shift for all three polymers. 
The Hb proton of TP showed no change in the presence of PEG and a downfield shift 
in the presence of PVP and in the presence of PVP-VA, which contrasted with TP in 
PVP-VA alone (Table 28). This indicates that hydrogen bonds between FFA and TP 
were disturbed by the polymer as well as the dimerization of the TP molecules. In the 
presence of 0.5mg/ml (Table 30), a slight change was seen for the Hj proton in the 
presence of PEG and a large change was seen in the presence of PVP and PVP where 
the down-fielding effect increased to Δδ = 0.025 for both. The Hh proton also showed 
an increase in the up-field shift of Δδ = -0.001, Δδ = -0.006 and Δδ = -0.005 for PEG, 
PVP and PVP-VA respectively.  
The chemical shifts of the Hb, Hc and the Hd protons did not show significant change 
indicating that the chemical environments of the TP protons did not change much. In 
the presence of 1mg/ml polymer (Table 32), a further increase was seen for the 
chemical shifts of Hj protons of FFA in the presence of PVP and PVP-VA - Δδ = 0.048 
for PVP and Δδ = -0.032 for PVP-VA. Hh protons also showed a slight increase in the 
presence of PEG and PVP - Δδ = -0.002 and Δδ = -0.009 respectively – while PVP-VA 
remained the same. Furthermore, the Hb proton showed a slight increase in the 
presence of PVP and PVP-VA and no change in the presence of PEG. The chemical 
environments for Hc and Hd protons remained the same. The results indicate that PVP 
interacted the most with the carbonyl functional group of FFA followed by PVP-VA then 
PEG. The 1mg/ml PVP-VA interacted with the dimerization of TP while no significant 
change was seen in the presence of other polymers in all three concentrations. This 
indicates that the chemical environment change was due to the hydrophobic/hydrophilic 
nature of the polymer and not due to hydrogen bond formation. 
Regarding the FFA-NIC co-crystal, at a low polymer concentration of 200g/mL in 
CDCl3, characteristic chemical shifts of the Hj proton of FFA moved downfield while Hh 
protons in the presence of PEG and PVP moved up-field. The Hc proton on the NIC 





presence of PVP and a downfield shift of Δδ = 0.001 in the presence of PVP-VA . The 
Ha protons show a downfield shift (Δδ = 0.003) in the presence of PEG, a large upfield 
shift (Δδ = -0.032) in the presence of PVP and a downfield shift (Δδ = 0.005) in the 
presence of PVP-VA. In the presence of 0.5mg/ml polymer (Table 32), a large downfield 
shift was seen for the Hj proton on FFA in the presence of PVP and PVPVA (Δδ = 0.020 
and Δδ = 0.018 respectively) and a moderate up field shift for the Hh proton. No 
significant change was seen for the Hc protons of NIC and a moderate down-field shift 
was seen in the presence of PEG (Δδ = 0.008) and PVP-VA (Δδ = 0.006). In the 
presence of 1mg/ml polymer, a high down-fielding shift occurred for the Hj proton on 
FFA in the presence of PVP and PVP-VA (Δδ = 0.022) and a moderate up-field shift for 
the Hh proton in the presence of all three polymers. No significant change was seen for 
the Hc proton on NIC and a large downfield shift was seen for the Ha proton in the 
presence of PEG (Δδ = 0.018), PVP (Δδ = 0.010) and PVP-VA (Δδ = 0.010). These 
results suggest that some of hydrogen bonds between FFA and NIC have been 
disrupted due to the interactions of FFA and polymer with PVP being the best polymer.  
In the solid state of 1:1 FFA-NIC co-crystal structure, hydrogen bonds are formed by 
two FFA and two NIC molecules, where Hj of carboxyl acid of the FFA and aromatic N 
of the first NIC form a hydrogen bond and the amide Ha or Hb of the second NIC forms 
a hydrogen bond with the carbonyl O atom of the acid of the same FFA [140]. It seems 
that same interactions of FFA and NIC are formed in CDCl3, indicating the de-shielding 
of chemical shifts of the Hj of FFA and Ha of NIC to a down-field when equal molar of 
FFA and NIC are dissolved in CDCl3 and therefore disrupting the intramolecular N-
Hj∙∙∙O=C bond of the co-crystal.  
For CBZ-NIC, in the presence of 0.3mg/ml polymer (Table 29), no significant change 
was seen for the chemical shift of Ha proton of CBZ in the presence of PEG and PVP 
and a small downfield effect was seen in the presence of PVP-VA (Δδ = 0.001). For the 
Hb proton, no change was seen in the presence of PEG, a slight down-field shift of Δδ 
= 0.001 was seen in the presence of PVP and a large up-field shift of Δδ = -0.16 was 
seen in the presence of PVP-VA. The Hc bond of NIC shows a down-field shift in the 
presence of PEG (Δδ = 0.001), PVP (Δδ = 0.001) and PVP-VA (Δδ = 0.002). The Ha 
proton showed an up-field shift of Δδ = -0.027 in the presence of PVP-VA which 
suggests that PVP-VA was able to disrupt the bonds formed by CBZ and NIC. 
Increasing the polymer concentration to 0.5mg/ml (Table 31) the Ha proton of CBZ 
shows a slight downfield change in the presence of all three polymers. The Ha proton 
of NIC shows a moderate down-field shift in the presence of PEG (Δδ = 0.010), PVP 





was seen for the CBZ Ha proton, and Hb proton showed a moderate down-field shift in 
the presence of PVP-VA whereas Hc proton on NIC shows a moderate downfield shift 
and Ha proton shows a large down field shift in the presence of PEG, PVP (Δδ = 0.021) 
and PVP-VA (Δδ = 0.030). The results indicate that PVP and PVP-VA at a concentration 








 7.3.3 Diffusion coefficient   
 
7.3.3.1 In presence of 0.3mg/ml of PEG/PVP/PVP-VA 
 





Diffusion coefficient 10^10 cm2/sec 
Drug - - Without polymers PEG PVP PVPVA 







9.425 8.597 8.235 8.501 8.751 
8.047, 8.061 8.301, 8.612 8.041, 8.561 8.212, 8.593 
8.580,   
8.766 







7.812 8.886 9.083 8.93524 8.567 
3.646 9.251 8.445 9.36306 8.476 
3.470 8.877 9.112 9.03541 8.672 










NIC 9.006 13.687 13.341 13.489 12.877 







9.425 8.309 8.452 8.285 8.465 
8.047, 8.061 8.159, 8.135 8.385, 8.003 8.128, 7.891 8.483, 8.075 
TP 
7.812 8.392 8.284 8.367 8.466 
3.646 8.357 8.287 8.497 8.432 
3.470 8.552 8.311 8.564 8.344 







9.425 8.869 8.665 8.264 7.852 
8.047, 8.061 8.293, 8.386 8.274, 8.327 7.970, 8.529 7.742, 7.568 
NIC 9.006 11.882 11.620 11.223 10.930 







6.935 10.562 9.994 10.012 9.790 
4.418 9.769 9.963 10.077 9.811 


















6.935 9.764 9.965 9.415 9.820 
4.418 9.582 9.659 9.545 9.667 
NIC 9.006 12.624 12.932 12.267 13.011 




















7.3.3.2 In presence of 0.5mg/ml and 1mg/ml of PEG/PVP/PVP-VA 
 








Diffusion coefficient 10^10 
cm2/sec in PEG  
Diffusion coefficient 10^10 
cm2/sec in PVP  
Diffusion coefficient 
10^10 cm2/sec in PVPVA  
0.5mg/ml 1mg/ml 0.5mg/ml 1mg/ml 0.5mg/ml 1mg/ml 









9.425 8.543 8.392 8.445 8.241 7.933 8.389 8.276 
8.047, 8.061 8.243, 8.580 8.355, 8.541 
8.552, 
8.289 














7.812 8.827 9.000 8.661 8.663 8.338 8.969 8.500 
3.646 9.210 8.25911 7.938 8.604 8.307 8.780 8.285 
3.470 8.820 8.97918 8.342 8.480 8.406 8.975 8.332 






















9.425 8.268 8.140 8.270 8.010 7.689 8.015, 7.911 
8.047, 8.061 8.137, 8.089 8.151, 8.072 
8.061, 
8.558 






7.812 8.392 8.529 8.540 8.143 8.326 8.465 8.293 
3.646 8.330 7.268 8.416 8.438 8.409 8.549 8.292 
3.470 8.543 8.622 9.076 8.130 8.384 8.653 8.387 









9.425 8.824 8.396 8.657 8.298 7.838 8.247 8.224 
8.047, 8.061 8.271, 8.367 8.146, 8.272 
8.232, 
8.948 





NIC 9.006 11.860 11.621 11.561 11.620 11.320 11.648 11.508 









6.935 10.501 9.838  9.707 9.762 10.226 9.776 9.708 
4.418 9.737 9.671 9.435 9.683 9.827 9.648 9.617 












NIC 9.006 12.932 13.025 12.603 13.109 12.506 12.920 12.613 









6.935 9.719 9.385 9.385 10.071 9.492 10.688 9.413 
4.418 9.556 9.429 9.233 9.482 9.808 9.458 9.275 
NIC 9.006 12.609 12.34009 11.990 12.574 12.270 13.067 12.083 















Table 37 - Summary of Diffusion coefficient corresponding to the Hj peak of FFA 
 

















Table 38 - Summary of Diffusion coefficient corresponding to the Ha peak of CBZ 
 



















Diffusion coefficient (DC) can be used as a means to measure the size and structural 
information of particles [349]. 2D DOSY spectra were measured and the diffusion co-
efficient of the drugs, co-formers and polymers were identified based on the 
characteristic peaks. The values of DC are shown in tables 35 and 36 followed by a 
summary of the Hj peak of FFA and Ha peak of CBZ in Tables 37 and 38 respectively. 
An example of the 2D spectrum of FFA in the presence of PEG is shown below. All 2D 
DOSY spectra can be found in the Appendices A6.  
 
Figure 30 - 2D DOSY spectrum of FFA and PEG in CDCl3 
 
 
Addition of 0.3mg/ml polymers to FFA drug molecules in chloroform altered the diffusion 
coefficient of the drug. In the presence of PVPVA, the diffusion coefficient increased to 
8.751 from 8.597 but decreased in the presence of PEG and PVP. The diffusion 
coefficients of PEG decreased while an increase was seen for PVP and PVP-VA (Table 
35). Increasing the polymer concentration to 0.5mg/ml and 1mg/ml polymer (Table 36), 
the diffusion coefficient of FFA decreased all three polymers, with the biggest decrease 
seen in the presence of PVP as shown in table 37 which suggests hydrogen bond 
formation between FFA and PVP molecules.  
TP, in the presence of 0.3mg/ml and 0.5mg/ml, the diffusion coefficient corresponding 
to the characteristic peak 7.8 (Hb proton), increased in the presence of PEG and PVP 
and decreased in the presence of PVP-VA. In 0.3mg/ml polymer, the DC corresponding 





VA and increased in the presence of PVP while the peak corresponding to 3.4 (Hd 
proton), decreased in the presence of PEG and PVP-VA and increased in the presence 
of PVP (Table 35). The diffusion coefficient of PEG, PVP and PVP-VA also increased 
which suggests no interaction was taking place between the polymers and TP. A 
decrease in the DC of the drug could be due to the self-association of the TP molecules. 
In the presence of 0.5mg/ml polymer, the DC decreased for the 3.6 characteristic peak 
(Hc proton) in the presence of all three polymers while the 3.4 peak shows an increase 
in the presence of PEG and PVP-VA and a decrease in the presence of PVP. In the 
presence of 1mg/ml polymer, a decrease in the DC was seen for all characteristic peaks 
of TP. A decrease in the polymer DC was seen in the presence of 1mg/ml PEG, 
0.5mg/ml PVP and 1mg/ml PVP which suggests hydrogen bond formation between the 
TP molecules and polymers in the specified concentrations (Table 36).  
NIC (corresponding to the ratio of FFA) shows an increase in the DC in the presence of 
0.5mg/ml PEG and a decrease in the presence of all other polymers in 0.3mg/ml, 
0.5mg/ml and 1mg/ml concentrations. NIC (corresponding to the ratio of CBZ), in 
0.3mg/ml concentration, decreased in the presence of PEG, and increased in the 
presence of PVP and PVP-VA. DC of NIC increased in the presence of 0.5mg/ml and 
1mg/ml PEG and decreased in the presence of all other polymers. 
In the presence of 0.3mg/ml polymer the 6.9 characteristic peak of CBZ showed a 
decrease in the presence of all three polymers while the 4.4 characteristic peak showed 
an increase the presence of all three polymers. The DC of the polymers also increased 
suggesting that no interactions were taking place between the polymer and CBZ 
molecules. In the presence of 0.5mg/ml and 1mg/ml polymers, the DC of CBZ 
decreased in all three polymers. The DC of polymers decreased in the presence of 
0.5mg/ml PVP and PVP-VA and in 1mg/ml PVP-VA suggesting hydrogen bond 
interactions with CBZ. 
The DC of FFA in FFA-TP decreased in comparison to FFA alone. In 0.3mg/ml polymer 
concentration, the DC was further decreased in the presence PVP while an increase 
was seen in the presence of PEG and PVP-VA. A large decrease was also seen on the 
DC of PVP which suggests hydrogen bond formation between PVP and FFA molecules. 
0.5mg/ml and 1mg/ml polymer concentration also show a decrease in the DC of FFA 
molecules with the largest decrease seen in the presence of 1mg/ml PVP as seen in 
Table 37. The DC of FFA in FFA-NIC also decreased in the presence of all three 





presence of 1mg/ml PVP. In the presence of 0.3mg/ml, the largest decrease was seen 
in the presence of PVP-VA.  
Regarding CBZ-NIC, the DC of CBZ decreased in comparison to CBZ alone. An 
increase was seen in the DC of CBZ in the presence of 0.3mg/ml PEG and PVP-VA 
polymer while a decrease was seen in the presence of PVP. Increasing the polymer 
concentration to 0.5mg/ml, the 6.9 characteristic peak showed an increase in the DC of 
CBZ in the presence of PVP and PVP-VA while a decrease was seen in the presence 
of PEG. The DC corresponding to the characteristic peak 4.4, showed a decrease in 
the presence of all three polymers. Increasing the polymer concentration to 1mg/ml 
showed a decrease in the DC for CBZ in the presence of all polymers, except for DC 
corresponding to the characteristic peak 4.4 in the presence of PVP. DC of polymer 
shows a decrease for 0.5mg/ml PVP and 1mg/ml PVP-VA indicating hydrogen bond 
formation.  
 
7.4 Discussion  
 
In this chapter, we have demonstrated the molecular interactions between drugs (FFA 
and CBZ) and co-formers (TP and NIC) in the presence of 0.3mg/ml, 0.5mg/ml and 
1mg/ml polymers (PEG, PVP and PVP-VA) in CDCl3. The mechanism of the effects of 
the polymers on the dissolution surface of co-crystals has been explored in our recent 
publication [350], and in the previous chapter indicating that a pre-dissolved polymer 
can interact with the crystal surface to alter the co-crystal dissolution properties, 
therefore inhibiting the drug precipitation. PEG, PVP and PVP-VA are water soluble 
polymers. However, due to their differences in molecular structures, the intermolecular 
interactions of polymer/drug and polymer/co-former are different, which affects the 
dissolution properties.  
PEG showed very little interaction with either FFA or CBZ in solution. At higher 
concentrations of 0.5mg/ml and 1mg/ml, and in the presence of TP or NIC, a moderate 
downfield shift was seen for FFA. No significant interactions were seen for CBZ. Our 
recently published research, also presented in chapter 6, suggested PEG forms very 
weak interactions with the surfaces of co-crystals and AFM and SEM results (chapter 
5) showed recrystallization of the parent drug suggesting PEG was not a good 
precipitation inhibitor [350]. NMR spectroscopy and DOSY spectroscopy also supports 
this conclusion as no significant interaction was seen with the drug molecules, 





alter the diffusion coefficient values suggesting any decreased values could be due to 
recrystallisation or self-association of the drug and not due to interactions with the 
polymer.  
The downfield chemical shifts of Hi of FFA in FFA-TP or FFA-NIC co-crystal indicated 
the formation of the hydrogen bonding interactions of FFA with PVP or PVP-VA in 
solution, with PVP showing a greater effect. This was also supported by the diffusion 
coefficient values decreasing in the presence of PVP or PVP-VA. Compared with PVP, 
PVP-VA is more hydrophobic and flexible due to the presence of a hydrophobic 
monomer vinyl acetate (VA), and leads to the formation of micelles at a higher 
concentration. PVP-VA micelle formation has been studied by our research group and 
it was found that critical micelle formation occurred at 1mg/ml of PVP-VA and at 
concentrations above 1mg/ml, solubility of PVP was elevated [178].  
The up-field chemical shifts of Hj of FFA in a higher PVP-VA concentration suggests 
the encapsulation of FFA in PVP-VA micelles. In the presence of a co-former of NIC or 
TP in solution, a significant increase in the solubilization ability of PVP-VA was 
observed. This was consistent with the diffusion coefficient values which decreased in 
the presence of PVP-VA due to interactions between the drug and polymer. The 
downfield shift Hb proton in CBZ in the presence of PVP-VA suggests interactions 
between the drug and polymer, also supported by a reduction in the diffusion coefficient 
value. A further decrease in the diffusion coefficient of CBZ was seen in the presence 
of NIC. Increasing the concentration of PVP-VA from 0.3mg/ml to 1mg/ml increased the 
interaction with FFA or CBZ with PVP-VA suggesting PVP-VA to be a good solubilising 
agent regardless of its concentration. This was consistent with previously published 
research by Guo who concluded PVP-VA to be a good solubilising agent and PVP to 
be a good stabilising agent for FFA [178].   
The elevated solution concentrations obtained by PVP-VA are fundamentally different 
from supersaturation solutions generated in the presence of the stabilizing agent PVP. 
Solubilizing additives increase concentration by increasing the equilibrium solubility 
rather than increasing the chemical potential. In conclusion, the solubility of FFA or CBZ 
co-crystal formulation is determined by the combination of several factors such as the 
type of a polymer, the polymer concentration and co-former present: in particular, the 







7.5 Chapter conclusion 
 
In this work, the mechanism of the supersaturated solution in the presence of polymers, 
the atomic-level information of molecular interactions among the parent drug, co-
formers and polymers were studied using one-dimensional proton nuclear magnetic 
resonance (1H NMR) spectroscopy and DOSY spectroscopy. The study showed that 
the type of a polymer, its concentration, and the interaction of the polymer with a co-
former in solution will significantly affect the FFA and CBZ co-crystals. It was found that 
PEG did not make a significant effect on the parent drugs. Furthermore, the role of PVP 
as a stabilising agent did not change for FFA even in the presence of co-formers. PVP-
VA on the other hand acts as a good solubilizer even at low concentrations.  
Solution 1H NMR and DOSY spectrometry is a powerful tool in which the atomic-level 
knowledge of molecular interactions among parent drug (FFA and CBZ), co-formers 
and polymers have been uncovered. In conclusion, to design an optimal co-crystal 
formulation, the scientific approaches through mechanistic understanding of the 
molecular state of drug molecules among API, co-former and plyometric excipients 




















Chapter 8 – Investigating the influence of 
polymers on drug molecules in solution 
using Molecular Modelling Techniques 
 
8.1 Chapter overview 
 
Molecular interactions between small drug molecules, water and polymer play a key 
role in the formulation of medicinal products. It is important to investigate the 
fundamental chemical interactions underlying dissolution of the co-crystals at molecular 
level in the presence of polymers. Although these interactions are well understood using 
experimental methods, using computational methods to accurately calculate binding 
energies still remain challenging. Molecular dynamics simulations are a powerful and 
promising approach to calculate binding energies between molecules.  
Previously our research focused on preventing surface precipitation by modelling the 
interaction of polymer molecules on the surface of single co-crystals. However, water 
molecules could not be incorporated due to increased computational time. This 
research focusses on the interaction of free co-crystal molecules in water in the 
presence of PEG, PVP or PVPVA. Interaction energies between drug-water, polymer-
water, co-crystal-polymer and co-former-polymer was calculated as well as the distance 
between the API molecules (length evolution and length distribution), mean squared 
displacement and radial distribution function. The pharmaceutical co-crystals used for 
this study are FFA-TP, FFA-NIC and CBZ-NIC. In previous research, these co-crystals 
have been extensively studied and characterized, showing that their dissolution 
behaviors could be regulated by including a polymeric excipient in the dissolution 














CSD 4.1.2 (The Cambridge crystallographic Data Centre, Cambridge, UK) and BIOVIA 
Material studio 2017 R2 was used to construct the simulation models. 
 
8.2.1 Construction of simulation model 
 
API and co-formers molecules were input from CSD and were geometry optimised 
(GO). Polymers were built using polymer builder on Materials studio and was GO. 
Anneal dynamics was performed from 100K to 1000K for 3 cycles to find the 
conformation of the polymers at minimum energy level. For the model, a 1:1 ratio of 4 
FFA/CBZ to co-former molecules was used along with 1500 water molecules and 2 
monomer units PEG/ 7 monomer units PVP or 6:4 monomer units PVPVA (6 monomers 
of PVP and 4 monomers of VA). Amorphous cell Calculation module on Materials studio 
was used for the construction of models. The density was set at 0.997g/cm3 to represent 
the density of water. COMPASS forcefield was used for all geometry optimisation and 
dynamics simulation methods as it is a widely used and reliable forcefield. The 
summation method used was Ewald for both Electrostatic and van der Waals forces 
respectively. The output structure was then geometry optimised using Steepest descent 
algorithm until minimum was reached. A visual representation of the system containing 
FFA and water is shown below after geometry optimisation. All other systems can be 
found in Appendices under A7.  







8.2.2 Dynamics simulations 
 
In order to contain all the water molecules inside the simulation box, the O atoms of 
each water molecule along the edges of the box was fixed in place by using the 
constraint method. The edged water molecules were allowed to rotate and change 
conformation in a fixed position while the other water molecules were free to move 
around. The simulations were performed using COMPASS forcefield, periodic boundary 
conditions at NVT ensemble, and a temperature of 298K for 50ps to equilibrate the 
system. The cut-off for non-bonded attractions, i.e., van der Waals and electrostatic 
forces, were 12.5Å. The simulations were then performed for another 50ps at NVE 
ensemble in order to acquire the production run needed for analysis with a frame output 
every 2ps. A visual representation of the system over time containing FFA-NIC and 
PEG in water is shown in Table 39. 
 
Table 39 - Simulation of FFA-NIC, PEG and Water at 0, 10, 20, 30 and 50ps 
 
















8.2.3 Calculating properties  
 
Length evolution and length distribution 
Length evolution and distribution was calculated by selecting the API molecules of 
interest and selecting ‘length evolution’ or ‘length distribution’ from the list of properties 
on the Forcite analysis dialog.   
Mean square displacement  
Mean square displacement (MSD) can determines the mode of displacement of 
particles followed over a defined period. It can help in determining whether the particle 
is freely diffusing, transported, or bound. The API molecules of interest was selected 







Radial distribution function 
 
Radial distribution function describes how density varies as a function of distance from 
a reference particle. The API−API radial distribution function is defined as the 
normalized probability of finding an atom of an API molecule at a radial distance r from 
an atom of any other API molecule. The oxygen atoms of the APIs and polymer were 
selected and ‘radial distribution function’ was selected from the properties on the Forcite 
analysis dialog. 
 
8.3 Results  
 
8.3.1 Calculating the energy of API molecules 
 
The Forcite module in materials studio was used to construct an energy expression that 
represents the potential energy surface by which the particles of a specified system 
interact. The total energy, van der Waals and electrostatic interactions of the API in the 
system containing API, polymer and water molecules was calculated at the start and 






Table 40 - Total energy, van der Waals and electrostatic interactions of API at the start of the production run in the presence of PEG, PVP and 
PVP-VA 
- 
Energy of API molecules in systems containing various polymers kcal/mol 
No polymer PEG PVP PVPVA 
- Total energy vdW Electrostatic Total energy vdW Electrostatic Total energy vdW Electrostatic Total energy vdW Electrostatic 
FFA 78.35 34.88 -79.59 65.06 51.74 -78.80 63.97 38.60 -71.55 73.88 41.80 -66.99 
FFA-TP 61.83 46.32 -78.90 49.19 45.56 -82.07 55.57 47.96 -76.30 66.07 31.97 -66.47 
FFA-NIC 52.69 41.87 -74.89 63.93 37.76 -76.37 55.85 40.10 -75.13 72.68 44.75 -78.71 
CBZ -115.11 24.54 -258.33 -133.84 19.81 -263.63 -93.72 29.82 -259.12 -72.69 31.75 -250.77 
CBZ-NIC -105.09 30.04 -261.03 -89.30 28.00 -261.52 -92.48 31.92 -265.78 -77.99 37.61 -263.29 
 
Table 41 - Total energy, van der Waals and electrostatic interactions of API at the end of the production run in the presence of PEG, PVP and 
PVP-VA 
-  
Energy of API molecules in systems containing various polymers kcal/mol 
No polymer PEG PVP PVPVA 
- Total energy vdW Electrostatic Total energy vdW Electrostatic Total energy vdW Electrostatic Total energy vdW Electrostatic 
FFA 58.82 48.81 -76.06 67.03 40.69 -71.01 52.16 44.41 -79.82 76.79 34.13 -67.82 
FFA-TP -42.83 38.08 -138.88 62.73 42.74 -76.71 56.08 39.65 -75.01 73.65 50.39 -71.58 
FFA-NIC 65.03 39.35 -75.35 52.01 45.78 -79.05 61.31 42.29 -78.984 61.56 48.76 -76.40 
CBZ -117.29 16.81 -258.85 -120.78 20.25 -263.65 -92.56 32.51 -262.20 -100.82 36.72 -261.44 






Table 42 - Summary of total energy, van der Waals and electrostatic interactions of 
API at the end of the production run in the presence of PEG, PVP and PVP-VA 
 FFA molecules CBZ molecules 
Total energy 
  









The API in FFA and FFA-TP systems shows a total energy decrease at the end of the 
production run (Table 41) in comparison to the start in the presence of no polymers 
(Table 40). FFA in FFA-TP also shows a large increase in the electrostatic attraction 
which indicates agglomeration of API molecules are occurring by the end of the 
simulation in the presence of no polymers. The total energy for FFA in FFA-NIC 
increases to 65.03 kcal/mol while the vdW and electrostatic interactions does not show 
much change which indicates FFA is more soluble in the presence of NIC. Previously 
in our research group we concluded FFA-TP shows bulk precipitation in the solvent 





In the presence of PEG, an increase in the total energy was seen for the API in FFA 
and FFA-TP systems (Table 42) while a decrease was seen for the electrostatic 
interactions which indicates the API is soluble in the presence of PEG. For FFA-NIC, a 
decrease was seen in the total energy while an increase was seen in the vdW and 
electrostatic interactions. In the presence of PVP, an increase in the total energy was 
seen for the FFA in FFA-TP system and a large decrease was observed for the 
electrostatic interactions, while a total energy decrease was seen for the FFA and FFA 
in FFA-NIC systems and an increase in the electrostatic interactions. This proposes 
PVP as a good precipitation inhibitor for FFA-TP CO while it is not effective for FFA-
NIC CO.   
In the presence of PVPVA, there is an increase in the total energy for FFA and FFA in 
FFA-TP system and a decrease in the electrostatic attractions is observed while the 
FFA in FFA-NIC showed a very slight increase as shown by table 42. CBZ in the 
presence of PVP and PVP-VA showed a decrease in the total energy while an increase 
was seen for the electrostatic interactions in the presence of all three polymers. On the 
other hand, CBZ in CBZ-NIC showed a decrease in the total potential energy as well 
as a decrease in the electrostatic interactions in the presence of all three polymers, with 
the biggest decrease being in the presence of PVP.  
The calculation of the energies of the API molecules indicate polymers do play an 
essential part in the formulation of co-crystals. The large decrease in the electrostatic 
attraction of FFA in FFA-TP at the end of the production run in comparison the start of 
the production run points towards agglomeration of the API molecules. Electrostatic 
interactions of FFA in FFA-TP are significantly decreased in the presence of polymers 
which indicates that the agglomeration of the FFA molecules are being disrupted by the 
presence of all three polymers, especially PVP-VA. The results obtained agree with the 
NMR and DOSY experiments presented in chapter 7 and shows that PVP-VA is the 
best polymer to use for FFA-TP and FFA-NIC COs while PVP is best suitable for CBZ-
NC CO.  
 
8.3.2 Calculating the kinetic properties of API molecules 
 
Forcite analysis tools were then used to analyse the simulation results during the 
production run in order to analyse the distance between the API molecules over a 50ps 
time period.  Plots can be produced showing the evolution of various different lengths 





mean squared displacement and radial distribution function was calculated for all FFA 
and CBZ molecules in various systems in the presence of PEG, PVP or PVP-VA.  
 
Length evolution and length distribution 
 
For visual purposes, only the FFA molecules of the of FFA-PVPVA model is shown 
below (Table 43) without the polymer and water molecules at different time interval. 
This model was used to calculate the length evolution and length distribution of the API 
molecules. All other models can be found in Appendices under A7. The length evolution 
and length distribution of the API in various systems was observed during the NVE 
production simulation run of 50ps. 
 
Table 43 - The evolution of bond lengths of FFA molecules at various time intervals in 
a 50ps production run. 






















Table 44 - Length evolution and length distribution of APIs with/without polymers over 
a 50ps production run. 




















Mean squared displacement and radial distribution function 
 
Table 45 - Mean square displacement and radial distribution functions of API 
molecules. 























The length evolution and length distribution of the APIs in various systems presented 
in Table 44, was observed after during the production simulation run of 50ps. FFA in 
the presence of polymers showed slight increase in the distances between the API while 
FFA alone showed a decrease. This is also supported by the length distribution graph 
where the probability of finding the API molecules at a shorter distance is higher than 
in comparison to the API molecules in the presence of polymers. Mean square 
displacement show the greatest movement for FFA was in the presence of PVP while 
the radial distribution function suggests strong interactions between the molecules as 
observed in the graphs in Table 45.  The weakest interactions are seen in the presence 
of PVP-VA.  
FFA in FFA-TP and in the presence of PEG and PVP-VA show a stable distance 
between the APIs over the 50ps time period. FFA in FFA-TP in the presence of PVP 
however, show a distance of 18Å, at the start of the production run which is much lower 
in comparison to the FFA alone or in the presence of PEG and PVP-VA (Table 44). The 
distance then continues to decrease over the course of time which suggests 
agglomeration of the API molecules is occurring in solution. The length distribution 
graph is also in agreement with the probability of finding the API molecules is at a 
distance of less than 30Å. FFA in the presence of FFA-TP also shows the largest mean 
square displacement in the presence of PVP with radial distribution function also 
showing the largest interactions between the O atoms (Table 45). Both FFA and TP 
molecules are able to self-associate with other molecules of the same species. In the 
presence of polymers, the self-association is disrupted, therefore agglomeration is not 
occurring.  
FFA molecules in FFA-NIC shows a similar pattern to FFA-TP with the API molecules 
precipitating in the presence of PVP. The probability of finding the molecules close 
together at short distances are higher in comparison to FFA-TP. Both the length 
evolution and length distribution (Table 44) suggest PEG and PVP-VA to be a good 
precipitation inhibitor as they prevent the API molecules from moving close together 
and the probability of finding the molecules close are low as shown by the length 
distribution graph. FFA molecules in FFA-NIC show the greatest movement in the 
presence of PVP as shown by the mean square displacement. However, the greatest 
interaction between the API molecules was seen in the presence of no polymers. FFA 
and NIC molecules are able to interact with each other and this interaction is disrupted 





CBZ alone and in the presence of PEG and PVP-VA shows a short stable distance 
between the molecules over the production run. In the presence of PVP, on the other 
hand, longer distances are seen at the start of the production run which is the 
maintained throughout. The distribution of the bond length shows that majority of the 
distances are above 22Å (Table 44). Mean square displacement for CBZ shows the 
largest movement in the presence of PVP-VA with the largest interactions also being 
present between the molecules in the presence of PEG and PVP-VA (Table 45).  
CBZ in CBZ-NIC however, show a promising effect in the presence of PVP-VA. The 
length between the API molecules is large in comparison to CBZ in the other systems. 
This is also supported by the bond length distribution which shows the probability of 
PVP-VA molecules found at longer distances in comparison to others (Table 44). CBZ 
molecules show the largest movement in the presence of PVP and the lowest 
movement in the presence of PVP-VA. Radial distribution function also show the lowest 
interactions in the presence of PVP-VA (Table 45).  
From the results gathered, it can be deduced that FFA molecules in FFA-TP and FFA-
NIC agglomerate in solution. Precipitation can be inhibited by the addition of polymers 
as both the NMR (Chapter 7) and molecular modelling results suggest. PVP is the worst 
polymer for FFA-TP and FFA-NIC formulations while PEG and PVP-VA show effects of 
inhibiting precipitation. PVP is the best polymer for CBZ formulation while PVP-VA is 
the most effective for CBZ-NIC formulations.  
 
8.5 Chapter conclusion 
 
This study explores the molecular interactions between the API molecules of FFA or 
CBZ in the presence of co-formers, various polymers and water molecules. The study 
showed that the type of a polymer and the interaction of the polymer with the drug in 
solution will significantly affect the FFA and CBZ co-crystals. It was found that in the 
presence of PVP, the FFA molecules in FFA-TP and FFA-NIC showed short distances 
and high interactions suggesting agglomeration of the drug is occurring. PVP-VA 
however is an effective precipitation inhibitor. Molecular modelling techniques proved 
to be a powerful tool which can be used to probe into the interactions of the drug 












This thesis has focussed on the dissolution properties of FFA-TP CO, FFA-NIC CO and 
CBZ-NIC CO in the presence of three different polymers using a combined experimental 
and molecular modelling techniques. Both the surface dissolution mechanism and the 
mechanism of molecular dissolution in solution has been investigated in order to give a 
better understanding for the formulation of the co-crystals. The specific aims of this 
study were to: 
1) explore the surface dissolution of single co-crystals in the presence/absence of 
polymers in solution by the use of non-contact Atomic force microscopy, Raman 
spectroscopy and Scanning electron microscopy to detect any surface change. 
2) at interaction of polymers on surface of single co-crystals by using molecular 
modelling techniques. 
3) explore the interactions of drug-drug, drug-polymer and co-former-polymer 
in solution by using NMR spectroscopy and DOSY.  
4) explore the interactions of free drug molecules, co-former molecules and 
monomers in the presence of water molecules using molecular modelling 
techniques. 
The influence of the three polymers PEG, PVP, and PVP-VA on the surface 
recrystallisation of FFA-TP CO, FFA-NIC CO and CBZ-NIC CO has been investigated 
using non-contact atomic force microscopy and scanning electron microscopy. FFA-
NIC and CBZ-NIC showed recrystallisation on the surface which was identified using 
Raman spectroscopy. The parent drug of FFA III and CBZ dihydrate had recrystallized 
on the surface of FFA-NIC CO and CBZ-NIC CO respectively while FFA-TP showed no 
precipitation on the surface but could have precipitated in the bulk solution.  
The dissolution mechanisms of FFA-TP CO are controlled by the defect sites of the 
crystal surface and by precipitation of the parent drug as individual crystals in the bulk 
fluid. In contrast, the dissolution mechanisms of FFA-NIC CO are controlled by the 
surface layer removal and by a surface precipitation mechanism, where the parent drug 





Both PVP and PVP-VA proved to be good surface precipitation inhibitors for FFA-NIC 
and could only partially inhibit the precipitation of CBZ-NIC.  
Molecular modelling techniques used to investigate the surface dissolution of the co-
crystals in the presence of polymers showed that PEG was not an effective inhibitor 
while PVP and PVP-VA was effective. In contrast to PVP-VA, PVP had greater 
interaction energies and was more effective in inhibiting parent drug precipitation in 
comparison to PVP-VA.  
Solution 1H NMR and DOSY spectrometry proved to be a powerful tool in which the 
atomic-level knowledge of molecular interactions among parent drug, co-formers and 
polymers can be explored. It was found that the type of a polymer, its concentration, 
and the interaction of the polymer with a co-former in solution will significantly affect the 
FFA and CBZ co-crystals. Results show that PEG did not make a significant effect on 
the parent drugs. Furthermore, the role of PVP as a stabilising agent did not change for 
FFA even in the presence of co-formers. PVP-VA on the other hand acts as a good 
solubilizer even at low concentrations.  
Finally, molecular modelling of the drug molecules in solution in the presence of co-
formers, polymers and water molecules showed that in the presence of PVP, the FFA 
molecules in FFA-TP and FFA-NIC showed short distances and high interactions 
suggesting agglomeration of the drug is occurring. PVP-VA however is an effective 
precipitation inhibitor.  
 
9.2 Future work 
 
The future directions can focus on carrying out animals testing and finally commercial 
co-crystal products. Up until now, animal studies to explore bioavailability of co-crystals 
are rare. Current research on pharmacokinetic (PK) studies of co-crystals have been 
focussing on comparing the bioavailability of co-crystals with pure drugs. However, little 
is known about the modification of PK of the studied drugs due to the presence of co-
former molecules in the GI tract. The underlying mechanisms of PK interactions of 
drugs, co-formers and polymers needs to be explored before commercial co-crystals 
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Table 1: Peak position and assignment of FFA-TP 
 Peak position (cm3) Assaignment  
FFA I 3322 -N-H 
2647 O-H acid 
1651 C=O 
1330 C-F 
TP 3119 -N-H 
1657 C=O 
1184 C-N 
FFA-TP PM 3317, 3110 -N-H  




FFA-TP CO 3282, 3070 -N-H  
2838 O-H (acid) 
1643 C=O 
1321 C-F 
FFA-TP SC 3272, 3060 -N-H  












Table 2: Peak position and assignment of FFA-NIC 
 
 Peak position (cm3) Assignment  
FFA I 3322 -N-H 
2647 O-H acid 
1651 C=O 
1330 C-F 

















Table 3: Peak position and assignment of CBZ-NIC 
 
 Peak position (cm3) Assaignment  
CBZ III 3464 -N-H 
1667 C=O 
800, 762 C-N-C 
647,623 (O-C-N) ring 
NIC 3362 -N-H 
1680 C=O 
CBZ-NIC PM 3464 -N-H of CBZ 
1676 C=O of NIC 
CBZ-NIC CO 3448, 3395 -N-H of CBZ 





CBZ-NIC SC 3448, 3395 -N-H of CBZ 















Before After 3D and % increase Before After 3D and % increase Before After 3D and % increase
Roughness, Ra (μm) 7.31 12.883 76.238 2.458 11.052 349.634 1.162 34.421 2862.220
Roughness, Ra  (μm) 10.712 18.578 73.432 3.347 20.812 521.811 2.191 24.915 1037.152
PVP
Roughness, Ra (μm) 9.898 8.15 -17.660 3.359 7.206 114.528 1.891 7.569 300.264
PVPVA





Before After    i Before After 3D and % increase Before After 3D and % increase
Roughness, Ra (μm) 1.827 0.105 5926.546 14.727 31.691 115.190 0.873 10.669 1122.108
Roughness, Ra  (μm) 1.814 21.678 095.039 1 .927 37.541 190.408 3.458 25.694 643.031
PVP
Roughness, Ra (μm) 1.079 31.384 08.619 13 716 15 914 16.025 0.972 4.042 315.844
PVPVA








A3 Scanning electron microscope 
 























A4 MD Simulations 
 





Table 2: Snapshot of a polymer on FFA (100) crystal surface at 298K at different 
simulation times 
 
Time (ps) FFA 
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A5 NMR Spectra 
 
Table 1: NMR spectra of the drugs and co-crystals in 0.3mg/ml polymer.  
 
Components 












































Table 2: NMR spectra of drugs and polymer in 0.5mg/ml polymer. 
 
Components 


































Table 3: NMR spectra of drugs and co-crystals in 1mg/ml polymer. 
 
Components 








































































Table 6: Peak shift in the presence of 0.3mg/ml, 0.5mg/ml and 1mg/ml of PEG, PVP and PVP-





Peak shift Difference of peak shift 
 
- - 
PEG PVP PVPVA PEG PVP PVPVA  
0.3mg/ml 0.3mg/ml 0.3mg/ml 0.3mg/ml 0.3mg/ml 0.3mg/ml  
2mg/ml FFA 
9.414 9.419 9.431 9.421 0.005 0.017 0.007  
8.053 8.053 8.05 8.051 0 -0.003 -0.002  
1.28mg/ml TP 
7.808 7.808 7.806 7.809 0 -0.002 0.001  
3.65 3.647 3.646 3.647 -0.003 -0.004 -0.003  
3.474 3.47 3.468 3.47 -0.004 -0.006 -0.004  
0.86mg/ml NIC 
9.006 9.007 9.007 9.007 0.001 0.001 0.001  
5.707 5.696 5.696 5.641 -0.011 -0.011 -0.066  
FFA-TP 
FFA 
9.423 9.427 9.438 9.427 0.004 0.015 0.004  
8.072 8.071 8.069 8.071 -0.001 -0.003 -0.001  
TP 
7.843 7.843 7.841 7.842 0 -0.002 -0.001  
3.658 3.657 3.656 3.657 -0.001 -0.002 -0.001  




9.519 9.521 9.522 9.522 0.002 0.003 0.003  
8.781 8.78 8.779 8.781 -0.001 -0.002 0  
NIC 
9.045 9.045 9.042 9.046 0 -0.003 0.001  
6.204 6.207 6.172 6.209 0.003 -0.032 0.005  
2mg/ml CBZ 
6.935 6.935 6.934 6.934 0 -0.001 -0.001  
4.417 4.417 4.419 4.419 0 0.002 0.002  
1.03mg/ml NIC 
9.005 9.007 9.006 9.005 0.002 0.001 0  




6.934 6.934 6.934 6.935 0 0 0.001  
4.443 4.443 4.444 4.427 0 0.001 -0.016  
NIC 
9.001 9.002 9.002 9.003 0.001 0.001 0.002  













Peak shift Difference of peak shift 
- - 
PEG PVP PVPVA PEG PVP PVPVA 
0.5mg/ml 1mg/ml 0.5mg/ml 1mg/ml 0.5mg/ml 1mg/ml 0.5mg/ml 1mg/ml 0.5mg/ml 1mg/ml 0.5mg/ml 1mg/ml 
2mg/ml FFA 
9.425 9.431 9.434 9.456 9.483 9.45 9.462 0.006 0.009 0.031 0.058 0.025 0.037 
8.047 8.046 8.045 8.043 8.038 8.044 8.042 -0.001 -0.002 -0.004 -0.009 -0.003 -0.005 
1.28mg/ml TP 
7.809 7.815 7.819 7.813 7.813 7.815 7.816 0.006 0.01 0.004 0.004 0.006 0.007 
3.646 3.648 3.649 3.648 3.648 3.648 3.648 0.002 0.003 0.002 0.002 0.002 0.002 
3.468 3.471 3.473 3.471 3.47 3.471 3.472 0.003 0.005 0.003 0.002 0.003 0.004 
0.86mg/ml NIC 
9.006 9.007 9.008 9.008 9.009 9.008 9.008 0.001 0.002 0.002 0.003 0.002 0.002 




9.423 9.429 9.434 9.448 9.471 9.448 9.455 0.006 0.011 0.025 0.048 0.025 0.032 
8.071 8.07 8.069 8.065 8.062 8.066 8.066 -0.001 -0.002 -0.006 -0.009 -0.005 -0.005 
TP 
7.841 7.84 7.84 7.839 7.836 7.84 7.834 -0.001 -0.001 -0.002 -0.005 -0.001 -0.007 
3.657 3.656 3.655 3.656 3.654 3.656 3.655 -0.001 -0.002 -0.001 -0.003 -0.001 -0.002 




9.551 9.558 9.563 9.571 9.573 9.569 9.573 0.007 0.012 0.02 0.022 0.018 0.022 
8.067 8.066 8.059 8.064 8.053 8.063 8.056 -0.001 -0.008 -0.003 -0.014 -0.004 -0.011 
NIC 
9.038 9.039 9.038 9.038 9.037 9.039 9.038 0.001 0 0 -0.001 0.001 0 
6.161 6.169 6.151 6.164 6.151 6.167 6.143 0.008 -0.01 0.003 -0.01 0.006 -0.018 
2mg/ml CBZ 
6.935 6.935 6.934 6.934 6.933 6.934 6.934 0 -0.001 -0.001 -0.002 -0.001 -0.001 
4.394 4.394 4.397 4.394 4.4 4.394 4.398 0 0.003 0 0.006 0 0.004 
1.03mg/ml NIC 
9.007 9.008 9.008 9.009 9.01 9.009 9.009 0.001 0.001 0.002 0.003 0.002 0.002 




6.932 6.933 6.931 6.931 6.93 6.931 6.93 0.001 -0.001 -0.001 -0.002 -0.001 -0.002 






9.002 9.003 9.007 9.003 9.008 9.004 9.006 0.001 0.005 0.001 0.006 0.002 0.004 







A6 DOSY Spectra 
 
Table 1: 2.4mg/ml drug in the presence of 0.3mg/ml polymer 
 
 FFA TP NIC 
CDCL3 
   
 
PEG 



















Table 2: 1:1 FFA-TP and 1:1 FFA-NIC CO in the presence of 0.3mg/ml polymer 
 



























Table 3: 2.4mg/ml CBZ, NIC and 1:1 CBZ-NIC CO in 0.3mg/ml polymer 
 
 CBZ NIC CBZ-NIC 
CDCL3 
   
PEG 























Table 4: FFA, TP and NIC with/without 0.5mg/ml polymers 
 
 FFA TP NIC 
CDCL3 
   
 
PEG 






   
PVPVA 










Table 5: 1:1 FFA-TP and 1:1 FFA-NIC with/without 0.5mg/ml polymers 
 



























Table 6: CBZ, NIC and 1:1 CBZ-NIC with/without 0.5mg/ml polymers 
 
 CBZ NIC CBZ-NIC 
CDCL3 
   
PEG 






















Table 7: FFA, TP and NIC with/without 1mg/ml polymers 
 












   
PVPVA 












Table 8: 1:1 FFA-TP and 1:1 FFA-NIC with/without 1mg/ml polymers 
 























Table 9: CBZ, NIC and 1:1 CBZ-NIC with/without 1mg/ml polymers 
 
 CBZ NIC CBZ-NIC 
CDCL3 
   
PEG 













Table 10: 0.5mg/ml and 1mg/ml of polymers 



































A7 Molecular dynamic simulations  
 
Table 1: systems after GO containing API, various polymers and water molecules. 
 










    
FFA-NIC 






















Table 2: Models used for length evolution and length distribution calculations 
 











    
CBZ 







    
 
 
 
